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ABSTRACT 
 
TDP43 is an ubiquitously expressed RNA-binding protein implicated in several 
aspects of RNA metabolism. It can shuttle between the nucleus and the cytoplasm; 
however, when it is mutated in some familial Amyotrophic Lateral Sclerosis (ALS) 
cases, it undergoes nuclear clearance and cytoplasmic accumulation, driving 
neuronal degeneration. The same phenotype is present in patients bearing ALS-
inducing mutations in other genes and ALS sporadic patients, defining TDP43 
proteinopathy as a common feature in this pathology. Why does it cause specific 
motor neuron death? 
Our quantitative proteomics analysis of the TDP43 interactome revealed the 
interaction with components of the mRNA surveillance pathway, suggesting a still 
undiscovered function in nonsense-mediated decay. We demonstrated that TDP43 
acts translation- and SMG1-dependently as a mRNA decay enhancer of specific 
transcripts by binding their 3’UTR. In particular, it leads to the down-regulation of 
transcripts with a long 3’UTR. 
From our sequencing data of spinal cords from TDP43Q331K transgenic mouse model 
and of motor neuron-like NSC-34 cells silenced for TDP43 emerged that TDP43 
plays another striking role in the 3’UTR, modulating mRNA alternative 
polyadenylation and promoting the generation of shorter transcripts. This finding is 
supported by the direct interaction of TDP43 with the cleavage stimulation factor, a 
core component of the polyadenylation machinery. 
These results broaden our knowledge of the role of TDP43 in the post-transcriptional 
gene expression regulation. The impairment of these two biological processes by 
TDP43 proteinopathy could have implications in ALS pathogenesis, representing 
possible new targets for therapeutic approaches. 
ABBREVIATIONS 
7 
 
ABBREVIATIONS 
 
ALS Amyotrophic Lateral Sclerosis 
APA  Alternative PolyAdenylation 
BP Biological Process 
CC Cellular Compartment 
CDS coding sequence 
cEJC canonical Exon Junction Complex 
CRISPR clustered regularly interspaced short palindromic repeats 
DEG  Differentially Expressed Gene 
DPG  Differentially Polyadenylated Gene 
DSMA  Distal Spinal Muscular Atrophy 
EJC Exon Junction Complex 
DIST Distal 
DSE Downstream Sequence Element 
fALS familial Amyotrophic Lateral Sclerosis 
GO Gene Ontology 
GWAS  Genome Wide Association Studies 
hnRNP heterogeneous nuclear RiboNucleoProtein 
IB  Inclusion Body 
KD Knockdown 
KO Knockout 
MF Molecular Function 
MND  Motor Neuron Disease 
MS Mass Spectrometry 
ncEJC non canonical Exon Junction Complex 
NB Northern Blot 
NES  Nuclear Export Signal 
NLS Nuclear Localization Signal 
NMD Nonsense-Mediated Decay 
OE Overexpressed 
ORF Open Reading Frame 
pAu polyAdenylation site usage 
PPI  Protein-Protein Interaction 
PROX Proximal 
PTC Premature Termination Codon 
RBP RNA Binding Protein 
RNP RiboNucleoProtein 
SILAC Stable Isotope Labeling with Amino acids in Cell culture 
sALS sporadic Amyotrophic Lateral Sclerosis 
SMA  Spinal Muscular Atrophy 
TARDBP TransActivation Response Element DNA-Binding protein 
USE Upstream Sequence Element 
UTR UnTranslated Region 
WB Western Blot 
WES  Whole-Exome Sequencing 
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1. INTRODUCTION 
 
1.1 AMYOTROPHIC LATERAL SCLEROSIS 
 
Amyotrophic lateral sclerosis (ALS) is a progressive and lethal neurodegenerative 
disease that affects upper and lower motor neurons (Figure 1.1), leading to 
weakness and paralysis of voluntary muscles and death from respiratory failure 
within 3-5 years after diagnosis. The onset of the disease occurs at a mean age of 
55 years, in 1-2 individuals per 100000 each year and the risk increases with age. 
More than 1 in 500 deaths in adults is caused by ALS (Taylor et al., 2016). 
The neurologist Jean-Martin Charcot diagnosed and described the first cases of ALS 
at the end of the 19th century (Kumar et al., 2011). The name of this condition 
reflects the muscle wasting ("a" for without, "myo" for muscle, "trophic" for 
nourishment) and the degeneration of motor neurons ("lateral" for the side of the 
spinal cord, "sclerosis" for hardening or scarring). In the United States, it is also 
referred to as Lou Gehrig's disease. 
 
Figure 1.1 Components of the nervous system targeted by ALS. The upper motor neurons project 
from the motor cortex into the brainstem and spinal cord;  the lower motor neurons innervate skeletal 
muscles and trigger their contraction (Taylor et al., 2016). 
 
1.1.1 THE GENETICS BEHIND ALS 
 
ALS is dominantly inherited in 10% of the cases (fALS), with a high penetrance. The 
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remaining 90% are sporadic cases (sALS) without a family history, even if they can 
have a genetic cause. In 1993 the first ALS-linked mutation affecting the SOD1 gene 
was reported, and in the next years, more than 50 putative ALS genes have been 
proposed. The gene identification strategies evolved along the years: linkage 
analysis, genome wide association studies (GWAS), whole-exome sequencing 
(WES) and genome sequencing (Bettencourt and Houlden, 2015). The confirmed 
causative genes of ALS are listed in Table 1.1; they are involved in RNA 
metabolism, protein quality control, dynamics of cytoskeleton, autophagy and axonal 
transport. ALS has a complex genetic architecture, and several risk genetic factors 
have been reported to contribute to its susceptibility; recent examples are Nek1 
(Kenna et al., 2016) and C21orf2 (van Rheenen et al., 2016). 
 
Table 1.1 ALS-causative genes 
Gene Protein Protein function Mutations 
ALS Year of 
discovery Familial Sporadic 
Sod1 
Cu-Zn superoxide 
dismutase 
Superoxide 
dismutase 
>150 20% 2% 1993 
Dctn1 Dynactin subunit 1 
Component of 
dynein motor 
complex 
10 1% <1% 2003 
Ang Angiogenin 
Ribonuclease/ 
RNA-binding protein 
>10 <1% <1% 2006 
Tardbp TDP43 RNA-binding protein >40 5% <1% 2008 
Fus FUS RNA-binding protein >40 5% <1% 2009 
Optn Optineurin Autophagy adaptor 1 4% <1% 2010 
Vcp 
Transitional endoplasmic 
reticulum ATPase 
Ubiquitin segregase 5 1-2% <1% 2010 
Ubqln2 Ubiquilin2 Autophagy adaptor 5 <1% <1% 2011 
C9orf72 C9orf72 
Possible guanine 
nucleotide 
exchange factor 
Intronic 
GGGGCC 
repeat 
34% 6% 2011 
Sqstm1 Sequestosome 1 Autophagy adaptor 10 <1% ? 2011 
Pfn1 Profilin-1 Actin-binding protein 5 <1% <1% 2012 
Hnrnpa1 hnRNPA1 RNA-binding protein 3 <1% <1% 2013 
Tuba4a Tubulin α-4A chain Microtubule subunit 7 <1% <1% 2014 
Chchd10 
Coiled-coil-helix-coiled-
coil-helix domain-
containing protein 10 
Mitochondrial 
protein of unknown 
function 
2 <1% <1% 2014 
Matr3 Matrin 3 RNA-binding protein 4 <1% <1% 2014 
Tbk1 
Serine/threonine-protein 
kinase TBK1 
Autophagy and 
inflammation 
regulator 
10 ? ? 2015 
Note: adapted from (Taylor et al., 2016) 
 
A common feature of ALS-affected neurons is the presence of cytoplasmic and 
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nuclear inclusion bodies (IBs) containing protein aggregates. In 2006, Virginia Lee 
and colleagues identified TDP43 as a component of the cytoplasmic ubiquitin-
positive, tau- and alpha-synuclein-negative inclusions present in sALS-affected 
neurons using a “brute force” monoclonal antibody approach coupled with bi-
dimensional electrophoresis and mass spectrometry analysis (Arai et al., 2006; 
Neumann et al., 2006). The importance of TDP43 in ALS pathogenesis increased in 
2008 by the identification of more than 40 ALS-linked missense mutations in the 
TARDBP gene (Figure 1.2b) (Pesiridis et al., 2009). 
 
1.2 TDP43 
 
The transactivation response element DNA-binding protein (TARDBP) gene on 
chromosome 1 codifies for TDP43, a DNA/RNA binding protein of 414 amino acids 
and 43 kDa, member of the heterogeneous nuclear ribonucleoprotein (hnRNP) 
family. It is ubiquitously expressed and highly conserved among mammals and 
invertebrates (Figure 1.2a) (Ayala et al., 2005). 
The protein structure, depicted in Figure 1.2a, presents an N-terminal domain, two 
RNA/DNA recognition motives (RRM1 and RRM2), which mediate the binding with 
single-stranded UG- or TG- repeats, but also with non-UG sequences (Buratti and 
Baralle, 2001; Tollervey et al., 2011; Bhardwaj et al., 2013; Lukavsky et al., 2013) 
and a glycine-rich C-terminal domain, which regulates interactions with other RNA-
binding proteins (Buratti et al., 2005) and TDP43 itself via a prion-like region 
(Polymenidou and Cleveland, 2011; Budini et al., 2012). The protein is located 
mostly in the nucleus in punctuated structures, designated as T-bodies (Wang et al., 
2002), due to the presence of a nuclear localization signal (NLS). The nuclear export 
signal (NES) instead allows it to shuttle to the cytoplasm, where it forms RNA 
granules, dendritic processing bodies (P-bodies) and stress granules (Wang et al., 
2007; Colombrita et al., 2009; Liu-Yesucevitz et al., 2010). 
TDP43 RNA interactome includes more than 6000 RNA species, and the TDP43 
binding is preferentially localized in introns, 3′ untranslated regions (3’UTRs) and 
non-coding RNAs (Polymenidou et al., 2011; Van Nostrand et al., 2016). 
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Figure 1.2 TDP43 in different species and in ALS. (a) Schematic representation of TDP43; the 
comparison with the orthologous genes (h, human; m, murine; d, Drosophila, ce, C.elegans) highlights 
its conservation among species (adapted from Vanden Broeck et al., 2014). (b) ALS-linked mutations 
are predominantly in the C-terminal domain (adapted from Pesiridis et al., 2009). 
 
1.2.1 TDP43 LOSS-OF-FUNCTION and/or GAIN-OF-FUNCTION IN 
ALS? 
 
TDP43 controls RNA metabolism at every stage of the RNA life cycle. It is involved 
in regulation of transcription (Ou et al., 1995; Lalmansingh et al., 2011) and multiple 
aspects of RNA processing and functioning. It plays a role in splicing of pre-mRNA, 
mRNA stability, transport from nucleus to cytoplasm and neurites, translation and 
microRNA processing (Buratti et al., 2001; Fiesel et al., 2009; Freibaum et al., 2010; 
Tollervey et al., 2011; Polymenidou et al., 2011; Ling et al., 2015) (Figure 1.3). 
 
Figure 1.3 Biological functions of TDP43 (adapted from Lee et al., 2012). 
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To understand how the ALS-linked mutations can affect the TDP43 functions and 
mediate the neurotoxicity, several models of gain- and loss-of-function have been 
established in different species (Feiguin et al., 2009; Lu et al., 2009; Sephton et al., 
2009;Wegorzewska et al., 2009; Kabashi et al., 2010; Xu et al., 2010; Li et al., 2010; 
Kraemer et al., 2010; Wu et al., 2010; Zhou et al., 2010; Stallings et al., 2010; Wils et 
al., 2010; Estes et al., 2011; Wang et al., 2011; Igaz et al., 2011; Xu et al., 2011). 
 
 
 
 
Box 1. Use of transgenic animals as an assay for the investigation of disease 
mechanism 
 
In the gain-of-function models, the overexpression of the mutated gene 
causes the disease, whereas the absence of the gene does not. If the 
overexpression of the wild type is also pathological, the effect is due to an increase 
of a normal function. Otherwise, it means that the mutation induces a novel toxic 
function. 
The mutation generates a loss-of-function when its presence decreases or 
abolishes the protein activity; in this case, the gene knockout in homozygosis or also 
in heterozygosis or the gene knockdown leads to the disease, which is not induced 
by the overexpression of the mutant or the wild type protein. 
A third disease model is a dominant-negative condition, where the allele with 
the mutation inhibits the function of the wild-type. Overexpression of the mutant 
gene and knockdown/knockout reproduce the pathological phenotype. 
Overexpression of the wild type is pathological only in some cases, as when it forms 
multi-protein complexes. 
 
Table 1.2 Transgenic animals as disease models 
Transgene expression 
Disease model 
Gain-of-function Loss-of-function Dominant negative 
mutant OE + - + 
wild type OE -/+ - -/+ 
KO or KD - + + 
Notes: positive (+) or negative (-) for disease phenotype; overexpression (OE); knockout (KO); 
knockdown (KD); adapted from Xu, 2012. 
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Based on the phenotype of transgenic animal models (Drosophila, zebrafish, 
rodents), high levels of both mutated and wild type TDP43 cause neurodegeneration. 
According to the gain-of-function model, the phenomenon can be explained by the 
increase of a regular function, which becomes toxic. 
However, a loss-of-function cannot be excluded, since neurological and 
neurodegenerative phenotypes are also shown in the absence of TDP43.  
These observations could be consistent with a dominant-negative model: TDP43 is 
part of ribonucleoprotein complexes, and when it is up- or down-regulated it alters 
their stoichiometry, rendering them dysfunctional. 
In the ALS-patients TDP43 is cleared from the nucleus, hyperphosphorylated, 
polyubiquitinated and cleaved (Neumann et al., 2006; Igaz et al., 2008). The 
produced 25 kDa fragment corresponds to the C-terminal part, has a high propensity 
for aggregation and sequesters the full-length TDP43 in cytoplasmic aggregates, 
which may induce a gain-of-cytotoxicity, but also a dysfunction of TDP43 and its 
complexes. In most of the ALS-cases, TDP43 is not mutated and may aggregate as 
a result of proteostasis impairment, causing the TDP43 pathology. Aggregation 
represents an hallmark of several neurodegenerative diseases (Kumar et al., 2016), 
even if the link between them, as well as the cause and effect relationship are still 
unclear. 
 
 
1.2.2 TDP43 AUTO-REGULATION 
 
TDP43 protein level is tightly controlled by a negative feedback loop, which depends 
on the interplay between splicing, 3’ end processing, and mRNA stability. 
TDP43 binds to its 3′ untranslated region and promotes RNA instability in an 
exosome-dependent way (Ayala et al., 2010). It also mediates the splicing in the 
3’UTR of its pre-mRNA, leading to introns removal. The presence of an exon junction 
complex (EJC) after the stop codon induces Tdp43 mRNA degradation by nonsense-
mediated decay (NMD) pathway (Polymenidou et al., 2011; Koyama et al., 2016). 
The mRNA decay can also occur through a NMD-independent mechanism, which 
involves spliceosomal assembly and/or intron 7 processing and produces a not fully 
processed pre-mRNA, retained in the nucleus and degraded (Bembich et al., 2014). 
1.  INTRODUCTION 
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Moreover, TDP43 overexpression blocks its canonical polyadenylation site (PAS) 
recognition and activates a cryptic PAS, promoting a nuclear mRNA retention 
mechanism (Avendaño-Vázquez et al., 2012; Koyama et al., 2016). 
These auto-regulatory mechanisms maintain the TDP43 homeostatic concentration, 
preventing its toxic up-regulation. It has been demonstrated in vivo and in vitro, that 
wild type and mutated TDP43 overexpression reduces the endogenous mRNA and 
protein level, whereas a lower expression of one allele is compensated by the up-
regulation of the other one (Xu et al., 2010; Ayala et al., 2011; Igaz et al., 2011; 
Polymenidou et al., 2011).  
 
1.3 NONSENSE-MEDIATED DECAY (NMD) 
 
Nonsense-mediated mRNA decay (NMD) is a translation-dependent pathway 
involved in mRNA surveillance and post-transcriptional gene expression regulation. 
NMD acts as a quality control mechanism, degrading abnormal transcripts with a 
premature termination codon (PTC) and preventing the synthesis of potentially toxic 
truncated protein isoforms (Losson and Lacroute 1979; Maquat et al., 1981). 
Transcriptional errors and genetic mutations are sources of defective mRNAs 
targeted by NMD. Alternative splicing is also able to introduce a PTC by translational 
frameshift alteration. Moreover, the removal of an intron in the 3’UTR generates an 
exon-exon junction after the canonical stop codon, causing the transcript 
degradation (Nagy and Maquat 1998). Also, NMD plays a physiological role, since it 
controls the abundance of several endogenous mRNAs, leading to their down-
regulation under specific cellular conditions. Examples of NMD-sensitive transcripts 
are mRNAs with upstream open reading frames (uORFs) or with abnormal 
extensions of their 3′ untranslated regions (3′UTRs) (Yepiskoposyan et al., 2011). 
In mammalian cells, NMD can be activated by two different mechanisms, which 
depend or not on the involvement of the exon junction complex (EJC), when a 
premature translation termination or a functionally equivalent improper termination 
event takes place. 
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1.3.1 EJC-DEPENDENT NMD 
 
The EJC is a dynamic protein complex (Figure 1.4) deposited 20-24 nucleotides 
upstream of exon-exon junctions in a sequence independent manner during pre-
mRNA splicing (Le Hir et al., 2000; Singh et al., 2012). It is assembled in the 
nucleus, remains associated with the mRNA during the nucleus-cytoplasm 
translocation and is removed during the “pioneer” round of translation by the 
ribosome machinery (Dostie and Dreyfuss, 2002; Sato and Maquat, 2009; Gehring et 
al., 2009). This round occurs at a distance of ∼430 nm outside the nucleus, within 5 
– 56 seconds after the entrance into the cytoplasm (Trcek et al., 2013) and displaces 
all EJCs located in the 5’UTR and the coding sequence. 
 
Figure 1.4 The Exon Junction Complex composition in the nucleus and cytoplasm. The EJC is 
a dynamic structure which tags the splice junction. It consists of a core complex, composed by 
eukaryotic translation initiation factor 4A3 (EIF4A3), cancer susceptibility candidate 3 (CASC3 or 
BARENTSZ, BTZ or MLN51), RNA-binding motif protein 8A (RBM8A or Y14) and mago-nashi 
homolog (MAGOH). It is also formed by splicing factors (RNPS1, DDX39B or UAP56, SAP18, 
ACINUS, PININ) and exporting factors (DDX39B, ALYREF, NXF1-NXT1). Some undefined RNA-
1.  INTRODUCTION 
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binding proteins (?), as well as SR proteins, promote the EJC recruitment and deposition and remain 
associated with the mRNA during its transport (Adapted from Le Hir et al., 2016). 
 
The EJC-dependent NMD (Figure 1.5) is based on the “50-55 nucleotides rule”. In 
the presence of an EJC located more than 50-55 nucleotides downstream of the first 
stop codon of the open reading frame, the ribosome stalls at this premature 
termination codon (Nagy and Maquat, 1998) allowing the recruitment of UPF1 (Up-
frameshift protein 1), SMG1 (Suppressor with Morphogenic effect on Genitalia 1), 
SMG8, SMG9, eRF1 and eRF3 (eukaryotic Release Factors 1 and 3) and the 
assembly of the Surveillance complex (SURF)  (Kashima et al., 2006; Ivanov et al., 
2008; Singh et al., 2008; Yamashita et al., 2009). The interaction of this complex with 
UPF2, UPF3b and the EJC forms the decay-inducing complex (DECID). SMG1 
phosphorylates and activates the NMD effector UPF1 (Czaplinski et al., 1995; 
Bhattacharya et al., 2000; Yamashita et al., 2001), leading to ribosome release and 
degradation factors recruitment. UPF1 is a RNA-dependent ATPase and ATP-
dependent RNA helicase which unwinds the RNA and removes the proteins from the 
NMD target. Following phosphorylation and possibly induced by ATP hydrolysis, 
UPF1 undergoes a conformational change that increases its affinity for RNA 
(Bhattacharya et al., 2000; Yamashita et al., 2001; Kashima et al., 2006; Chamieh et 
al., 2008; Franks et al., 2010; Shigeoka et al., 2012; Okada-Katsuhata et al., 2012; 
Fiorini et al., 2013;). At this point, the target mRNA is irreversibly committed to 
decay. SMG5, SMG6, SMG7, PNRC2 (proline-rich nuclear receptor coregulatory 
protein 2) and the protein phosphatase 2A (PP2A) are recruited. The endonuclease 
SMG6 cleaves the mRNA near the PTC (Huntzinger et al., 2008; Eberle et al., 2009); 
SMG5 and SMG7 promote mRNA deadenylation followed by decapping and 
exonucleolytic decay (Unterholzner and Izaurralde 2004); PNRC2 interacts with the 
decapping enzyme DCP1a; PP2A dephosphorylates UPF1 to make it accessible for 
the next round of NMD. The NMD target, without the 5′ cap and the 3′ poly(A) tail, is 
unstable and is degraded from both ends (Anders et al., 2003; Boehm et al., 2014; 
Chiu et al., 2003; Kurosaki et al., 2014; Lee et al., 2015; Ohnishi et al., 2003; 
Schmidt et al., 2015). 
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Figure 1.5 EJC-dependent NMD (Adapted from Kervestin and Jacobson, 2012). 
 
The EJC-dependent model does not fit with all the experimental data. For example, 
in some cases, NMD can be triggered by an EJC located less than 50 nucleotides 
upstream of the stop codon. Otherwise, in other cases, NMD can be insensitive to 
the presence of a PTC. Moreover, transcriptome-wide analysis of EJC deposition 
revealed that EJCs are not present upstream of all exon-exon junctions (Saulière et 
al., 2012, Mühlemann 2012); half of all EJCs are present at non-canonical positions 
(Figure 1.6), and it is still unknown if alterations of EJC deposition can affect the 
efficiency of the EJC-dependent NMD. 
 
 
Figure 1.6 Involvement of RNA binding proteins (RBPs) in EJC deposition. (a) The canonical 
EJC (cEJC) is assembled 20-24 nucleotides upstream the exon-exon junction. RBPs may be involved 
in the recruitment and the stabilization of the EJC core complex. (b) RBPs may influence the loading 
of EJC in non-canonical regions (ncEJC). (c) The absence of specific RBPs may affect negatively the 
stabilization of the EJC, which is disassembled (adapted from Le Hir et al., 2016). 
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1.3.2 EJC-INDEPENDENT NMD 
 
The NMD activation in eukaryotic cells can also be influenced by the distance 
between the stop codon and the cytoplasmic poly(A)-binding protein 1 (PABPC1) in 
an EJC-independent manner.  
During translation termination, PABPC1 interacts with eRF3 enhancing the release 
of the ribosome stalled at the stop codon and its recycling to the 5’ end of the same 
transcript (Figure 1.7a) (Hoshino et al., 1998; Amrani et al., 2004; Behm-Ansmant et 
al., 2007). However, some studies observed that the effect of PABPC1 on efficient 
termination is weaker in transcripts with a long 3’UTR. UPF1 binds promiscuously 
the cytoplasmic mRNA and is displaced by the translating ribosomes in the 5’UTR 
and in the coding region (Gregersen et al., 2014; Hogg and Goff, 2010; Hurt et al., 
2013; Kurosaki and Maquat, 2013; Kurosaki et al., 2014; Lee et al., 2015; Zünd et 
al., 2013); it  accumulates in the 3’UTR, where it can compete with PABPC1 for the 
interaction to eRF3 eliciting NMD (Figure 1.7b)  (Singh et al., 2008). This model 
leads to degradation of PTC-harbouring mRNA but is also involved in the regulation 
of endogenous transcripts. In general, the NMD targets are characterized by a 
termination codon that is not in a favorable environment for efficient translation 
termination (Amrani et al., 2006; Nicholson et al., 2010). 
.  
Figure 1.7 EJC-independent NMD. (a) Schematic representation of a normal translation termination 
and (b) how a long 3’UTR triggers EJC-independent NMD (Adapted from Kervestin and Jacobson, 
2012). 
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1.3.3 STAUFEN1-MEDIATED DECAY (SMD) 
 
In mammalian cells, another mRNA degradation process has been reported in 2005 
(Kim et al., 2005), the STAUFEN1-mediated mRNA decay (SMD). STAUFEN1 
binds STAUFEN1-binding sites (SBS) in the 3’UTR of target mRNAs. SBS are 
dsRNA structures formed by either intra-molecular (Figure 1.8a) or inter-molecular 
(Figure 1.8b) base-pairing (Gong and Maquat 2011). During the first round of 
translation, when the ribosome reaches a stop codon sufficiently upstream of an 
SBS, the bound STAUFEN1 is not removed, recruits the NMD effector UPF1 and 
enhances its helicase activity (Park et al., 2013), eliciting a splicing-independent 
mRNA decay. 
 
Box 2. Which are the physiological NMD targets and how can they be studied? 
The NMD program was described for the first time in a patient affected by beta-
thalassemia (Chang and Kan, 1979). Since then the human beta-globin gene has 
been used to develop RNA reporter systems to investigate deeper the mechanism 
(Maquat et al., 1981; Thermann et al., 1998). In particular, the tethering reporter 
assay was used to demonstrate the involvement of UPF1, Y14, RNPS1, PYM, and 
Barentsz in this pathway (Lykke-Andersen et al., 2000; Lykke-Andersen et al., 2001; 
Gehring et al., 2003; Bono et al., 2004; Palacios et al., 2004). Among the mRNA 
surveillance pathways, the nonsense-mediated decay is the most studied, and in the 
last years, the knowledge of this process is increased. However, the identification of 
NMD targets using high-throughput data remains challenging. Transcriptomic analysis 
revealed the up regulation of transcripts-lacking NMD features after UPF1 depletion, 
whereas many predicted NMD-targets remained unchanged in its absence. The 
hypothesis is that the presence of a PTC is a strong NMD-eliciting feature, but for 
what concern the physiological mRNA targets, their susceptibility to NMD may 
depend on more than one factor (Mendell et al., 2004; Wittmann et al., 2006). 
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Figure 1.8 STAUFEN1 mediated decay (SMD). STAUFEN1 binds the 3’UTR of its targets, through 
the recognition of STAUFEN1-binding sites (SBS), which can be (a) intra-molecular or inter-
molecular (b) dsRNA structures (adapted from Park and Maquat, 2013). 
 
 
 
1.4 ALTERNATIVE POLYADENYLATION (APA) 
 
Polyadenylation is a cotranscriptional maturation process by which premature 
messenger RNAs (pre-mRNAs) are cleaved and acquire a poly(A) tail at their 3’ end. 
This process involves almost all eukaryotic mRNA and other products of polymerase 
II, especially long non-coding RNAs (lncRNAs). In mammalian genome ~70% of 
genes and about half of the genes in flies, worms, and zebrafish present more than 
one polyadenylation site, leading to the formation of several transcripts with different 
3’ termini (Tian et al., 2005; Jan et al., 2011; Hoque et al., 2012; Derti et al., 2012; 
Smibert et al., 2012; Ulitsky et al., 2012). Alternative polyadenylation (APA) allows 
the differential usage of these sites, representing a post-transcriptional gene 
regulation mechanism spread across all eukaryotic species. 
 
1.4.1 MECHANISM OF POLYADENYLATION 
 
The 3’ end maturation is a two-step process, which involves specific endonucleolytic 
cleavage of the nascent RNA, followed by adenosine tail synthesis on the 3ʹ 
terminus of the cleaved product by poly(A) polymerase (PAP). The 3' end cleavage 
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and polyadenylation site selection in mammalian pre-mRNAs is controlled by cis-
acting RNA elements and trans-acting factors (Figure 1.9) (reviewed in Elkon et al., 
2013, Gruber et al., 2014; Tian and Manley, 2017). The polyadenylation signal (PAS) 
represents the leading cis-element; its canonical sequence is the hexanucleotide 
AAUAAA, even if more than ten weaker close variants are known (Derti et al., 2012), 
and it is mostly located 10–35 nucleotides upstream of the cleavage site. Other RNA 
elements upstream (UGUA elements, U-rich elements) and downstream (GU-rich or 
U-rich sequences) of the PAS, typically more than 40 nucleotides away, can 
enhance polyadenylation efficiency. The proteomic and structural characterization of 
the 3' end processing machinery identified the core processing factors and revealed 
the presence of other 50 proteins typically involved in other cellular processes (Shi et 
al., 2009). The polyadenylation machinery is composed of four complexes: Cleavage 
and Polyadenylation Specificity Factor (CPSF), Cleavage Stimulation Factor (CSTF), 
Cleavage Factor I and II (CFI, and CFII). Single auxiliary proteins are also involved: 
symplekin, poly(A) polymerase (PAP), poly(A)binding protein (PABP), 
retinoblastoma-binding protein 6 (RBBP6) and the C-terminal domain (CTD) of RNA 
polymerase II (RNApol II) largest subunit. CPSF recognizes the AAUAAA sequence, 
and CSTF binds to the downstream sequence element (DSE), cooperatively 
interacting one with each other and promoting the cleavage between their binding 
sites. CFI interact with the upstream sequence element (USE) and CFII cleaves the 
RNA, generating a CA 3' end for poly(A) tail extension (~200 residue length), which 
is catalyzed by PAP with the help of PABP.  
 
Figure 1.9 Factors involved in cleavage and polyadenylation during the 3’end maturation. 
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Trans-acting factors and their corresponding cis-acting RNA elements are colored similarly. Cleavage 
and Polyadenylation Specificity Factor (CPSF) contains CPSF1 (or CPSF160), CPSF 2 (or 
CPSF100), CPSF3 (or CPSF73), CPSF4 (or CPSF30), WDR33 and Fip1 (factor interacting with PAP) 
and specifically recognizes the polyadenylation signal (PAS) through CPSF1. The canonical 6-mer 
PAS and its variants are listed (Gruber et al., 2014). Cleavage Stimulation Factor (CSTF) is an 
hexamer composed by CSTF1 (or CSTF50), CSTF2 (or CSTF64, or its paralogue, τCSTF64), CSTF3 
(CSTF77) and its interaction with the downstream U-/GU-rich sequence element (DSE) is mediated 
by CSTF2. Cleavage factor I (CFI) is a tetramer which includes CFI25 and either CFI68 or CFI59 and 
binds the upstream U-rich/ UGUA sequence element (USE). Cleavage factor II (CFII) contains PCF11 
and CLP1 and assists the termination of the RNA Pol II-mediated transcription (adapted from Tian et 
al., 2013; Elkon et al., 2013; Gruber et al., 2014). 
 
1.4.2 CLASSIFICATION OF ALTERNATIVE POLYADENYLATION 
 
Polyadenylation events can be categorized into two classes, according to the 
splicing involvement (Figure 1.10a) (reviewed in Lutz and Moreira, 2011; Di 
Giammartino et al., 2011; Tian et al., 2013; An et al., 2013; Elkon et al., 2013). In the 
first class, multiple PASs are present within the last exon; the resulting mRNAs 
encode the same polypeptide chain, even if the protein amount can be affected. 
When the distal alternative polyadenylation signal is chosen, the 3’UTR length 
increases, introducing binding sites for regulatory elements, as RNA binding 
proteins, miRNAs, and lncRNAs, that can influence the mRNA stability, translation 
efficiency and cellular localization (Figure 1.10b). The second class combines 
alternative splicing with alternative polyadenylation; it involves PASs located in 
upstream introns or exons, generating mRNAs with different coding sequences. Both 
tandem and splicing dependent alternative polyadenylation generate transcripts with 
different 3’ ends, however, the downstream effects of these two processes at the 
protein level are not the same. 
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Figure 1.10 Classification of alternative polyadenylation. (a) Alternative polyadenylation events 
are divided into two classes. Discrimination of splicing dependent and independent mechanism is 
indicated. Schematic of the pre-mRNA with one or more alternative polyadenylation signal (left) and 
the relative mRNAs (right). Light gray boxes, exons; lines, introns; light blue boxes, untranslated 
regions; dark blue boxes, coding regions. (b) Splicing independent alternative polyadenylation 
generates mRNA products with different 3’ UTR length. A long 3’UTR can potentially contain more 
cis-regulatory sequences targeted by RNA binding proteins (RBPs), microRNAs (miRNAs), and long 
noncoding RNAs (lncRNA) (adapted from Lutz and Moreira, 2011; Di Giammartino et al., 2011; Tian 
et al., 2013; An et al., 2013; Elkon et al., 2013; Gruber et al., 2014; Tian and Manley, 2017). 
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Box 3. Methods for polyadenylation sites mapping 
The genome-wide mapping of polyadenylation sites and the quantitative analysis of 
APA changes can be achieved by several sequencing methods. Standard RNA-seq 
can be adopteded for this kind of analysis (Wang et al., 2008; Masamha et al., 2014; 
Prucendio et al., 2015). The identification of the 3′ ends can be performed by using 
reads with untemplated A-stretches. APA isoforms are quantified by comparing the 
density of the reads mapped only in the longer transcript with that of the reads in the 
common region. However, the presence of more than two APA isoforms may 
complicate the analysis. Moreover, RNA-seq needs a great sequencing depth since it 
is characterized by a low coverage at the extremities of the transcript (Figure 1.11). 
Other approaches (cDNA/EST-seq, PAS-seq, PASAS and PolyA-seq) rely on 
oligo(dT)-based cDNA synthesis for library preparation. Since they can be affected by 
oligo(dT) priming at internal A-rich sequences, different computational approaches 
have been implemented to reduce the false discovery rate (Mangone et al., 2010; 
Fox-Walsh et al. 2011; Shepard et al., 2011; Fu et al., 2011; Derti et al., 2012). In 3P-
seq and 3′ READS, 3′ end fragments are captured by RNA ligation, avoiding the 
internal priming issue, but the protocol requires more enzymatic steps, and the RNA 
ligation bias can affect quantitative performance (Jan et al., 2010; Hafner et al. 2011; 
Hoque et al., 2012). During direct RNA sequencing (DRS), the poly(A) RNAs are 
captured on oligo(dT) coated slides and directly sequenced on Helicos single-
molecule sequencing platform. The internal priming could still be a problem, even if 
the number of false positives reported in the literature is very low. In comparison with 
the Illumina system, the reads count is lower and the average read length is shorter. 
However, this technique is more quantitative, since individual RNAs are sequenced 
without possible biases introduced during library production, as RT- PCR or other 
enzymatic reactions (Ozsolak et al., 2010; Ozsolak and Milos 2011; Sherstnev et al., 
2012).  
,  
Figure 1.11 RNA-seq versus 3’end-seq. Coverage is plotted for all transcripts; mRNA-
seq gray area; 3’end-seq green area, spike-in control mix lines (from Mol et al., 2014). 
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1.4.3 ROLE OF RNA BINDING PROTEINS IN APA REGULATION 
 
The alternative polyadenylation mechanism is finely tuned; variations in the core 
factors expression level can cause differential PAS selection, unbalancing the 
relative ratio of the produced transcripts. For example, CFIm25 is a repressor of 
proximal poly(A) site usage and its knockdown leads to the production of shorter 
transcripts (Masamha et al., 2014). The up regulation of CSTF components 
promotes the usage of the proximal PAS and their silencing, in particular, the CSTF2 
depletion, results in an opposite phenomenon (Takagaki et al., 1996). 
The 3’ end processing can also be modulated by other RNA binding proteins, which 
compete and/or cooperate with the polyadenylation machinery, according to their 
binding site (Table 1.3) (Erson-Bensan, 2016). As previously explained, alternative 
polyadenylation and alternative splicing are interconnected processes. Therefore 
they can share RNA binding proteins which are involved in the regulation of both 
mechanisms. 
 
Table 1.3 RBPs involved in APA 
RNAbp Binding site Effect Reference 
hnRNP H proximal PAS Enhancer Katz et al., 2010 
CPEB1 USE of the proximal PAS Enhancer Bava et al., 2013 
PTB DSE Inhibitor Castelo-Branco et al., 2004 
Hu proteins DSE Inhibitor Zhu et al., 2007; Dai et al., 2012; Mansfield and Keene, 2012 
ESRP1/2 DSE Inhibitor Dittmar et al., 2012 
PABPN1 USE of the proximal PAS Inhibitor Jenal et al., 2012 
dSXL DSE Inhibitor Gawande et al., 2006 
dELAV proximal PAS Inhibitor Hilgers et al., 2012 
MBNL 
USE of the PAS Enhancer 
Batra et al., 2014 
PAS Inhibitor 
NOVA2 PAS Inhibitor Licatalosi et al., 2008 
FUS 
DSE of the PAS Enhancer 
Masuda et al., 2015 
USE of the PAS Inhibitor 
TDP43 
USE or close to the proximal PAS Inhibitor 
Rot et al., 2017 
DSE of the proximal PAS Enhancer 
Note: d = Drosophila; DSE  = downstream sequence element; USE  = upstream sequence element 
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1.4.4 MODELS OF REGULATORY MECHANISMS FOR PAS 
SELECTION 
 
The PAS selection is regulated by multiple mechanisms, acting in combination 
(reviewed in Shi, 2012). According to the survival of the fittest model (Figure 1.12a), 
the alternative polyadenylation outcome depends on the intrinsic affinity of the PAS 
with the polyadenylation machinery and the abundance of the core 3’ processing 
factors. The distal PAS is typically the strongest, presumably to ensure proper 
transcription termination; on the other hand, proximal PAS is transcribed earlier and 
has more time to be chosen. Elevated protein levels of the core processing factors 
promote the usage of the proximal PAS. When the factors are limited, the distal PAS 
is preferred. A concrete example of this model is the alternative polyadenylation of 
IgM mRNA. During B-cell activation, high level of CSTF2 results in shorter 
transcripts; however in resting B-cells the distal PAS is preferentially chosen, due to 
a limited presence of CSTF2 (Takagaki et al., 1996). The PAS selection can be 
enhanced or inhibited by regulatory factors, as explained by the agonist/antagonist 
model (Figure 1.12b); several examples are listed in Table 1.3. Moreover, 
alternative polyadenylation depends on the RNA polymerase II (RNApol II) 
processing (Figure 1.12c). High transcription activity is correlated with proximal PAS 
choice, while high transcription elongation rate promotes the usage of distal PAS. 
 
Figure 1.12 Mechanisms of regulation in PAS selection. The strong PAS is highlighted in red, the 
weak PAS in blue; yellow box, 3’ processing factor; green box, agonist factor; red box, antagonist 
factor; RNA is in light gray, DNA in dark gray (adapted from Shi, 2012).
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2. AIM 
 
Motor neuron diseases (MNDs) are a group of untreatable and lethal disorders 
characterized by progressive degeneration of upper and lower motor neurons in the 
central nervous system and gradual weakness of bulbar, limb, thoracic, and 
abdominal muscles. In most cases, these pathological conditions lead to paralysis of 
the voluntary muscles and a poor prognosis. 
The etiology is largely unknown; environmental, toxic, viral or genetic factors may be 
implicated in sporadic MNDs. Even if in some hereditary forms different mutations in 
ubiquitously expressed genes have been identified to be responsible for the selective 
death of motor neurons, it is still unclear which are the converging mechanisms 
underlying the phenomenon. 
Alterations in RNA metabolism are a common signature in different 
neurodegenerative pathologies. The RNA binding proteins represent critical players 
in the RNA-processing events and, when their functionality is compromised, 
deleterious consequences can arise for the cell. Many genes mutated in familial 
forms of MND are involved in RNA splicing, transport, stability, and translation. 
Among them, we mainly focused our attention on TDP43. The major objective of this 
study is to find out novel possible roles of TDP43, potentially impaired in ALS, and to 
analyze the molecular mechanisms through which TDP43 exploits its functions in 
vivo and in vitro, making use of high- and low-throughput proteomic and 
transcriptomic approaches, molecular assays and already published data. 
Another aim of the project is the generation of a panel of MND cell models, in which 
tagged wild type and mutated RNA binding proteins involved in Amyotrophic Lateral 
Sclerosis (ALS), Spinal Muscular Atrophy (SMA), and  Distal Spinal Muscular 
Atrophy type 1 (DSMA1) can be induced. The engineered motorneuron-like cells are 
suitable for in vitro studies, protein and RNA interactome analysis. 
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3. RESULTS: TDP43 AND NONSENSE-MEDIATED 
DECAY 
 
3.1 TDP43 INTERACTS WITH mRNA SURVEILLANCE PATHWAY 
COMPONENTS 
 
We quantitatively assessed the TDP43 protein interactome in the NSC-34 motor 
neuron-like cell line (Table 3.1 and Figure 3.1b) through SILAC-based proteomics 
(Figure 3.1a). We obtained an enrichment in components of the spliceosome 
(KEGG mmu03040, 34 interacting proteins, Fold Enrichment: 17.7, Enrichment p 
value 1.97e-34), the ribosome (KEGG mmu03010, 35 interacting proteins, Fold 
Enrichment: 16.8, Enrichment p value 1.64e-34) and the mRNA surveillance 
pathway (KEGG mmu03015, 12 interacting proteins, Fold Enrichment: 12.07, 
Enrichment p value 5.84e-15). We identified members of the exon-junction complex 
(EJC), two transient EJC interacting factors, and ten SR proteins. We also found the 
principal nonsense-mediated mRNA decay (NMD) effector UPF1, the phosphatase 
PPP2R1A, which dephosphorylates UPF1 for the next round of NMD, and the central 
NMD suppressor PABPC1. Referring to the study published by Singh and colleagues 
in 2012, our list of proteins bound by TDP43 is also enriched in components of EJC 
interactome (EJC-ome, fold enrichment: 15.5, p value = 1.38e-27). Among the other 
interactors, we found proteins involved in RNA processing, post-transcriptional gene 
expression regulation, and epigenetic gene silencing (Table 3.1). 
We validated the binding with the core EJC components Y14, EIF4A3, BTZ and with 
UPF1 and PABPC1 by immunoprecipitation and Western blot analysis (Figure 3.1c). 
Since the interactions that we tested are RNA-dependent (except for PABPC1), we 
wanted to understand if the enrichment in components of the mRNA surveillance 
pathway is specific for the TDP43 interactome or whether these proteins can be also 
present among the binders of other RNA binding proteins.  
We compared the immunoprecipitation of TDP43 with the pulldown of the FET family 
members FUS, EWSR1, and TAF15 (Figure 3.1d). The Western blot analysis 
revealed that the interaction of TDP43 with elements of the mRNA surveillance 
pathway, as UPF1 and EIF4A3, is a specific feature and it does not depends on its 
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intrinsic nature of RBP (Figure 3.1e). 
 
 
Figure 3.1 TDP43 interacts with the mRNA surveillance pathway. (a) Workflow of protein-protein 
interaction analysis by SILAC based q-AP-MS, Stable Isotope Labeling with Amino acids in cell 
culture based quantitative Affinity Purification coupled with high-resolution Mass Spectrometry (figure 
adapted from Paul et al., 2011). His-HA hTDP43 and His-HA GFP were overexpressed for 48 h in 
NSC-34 cell line cultured in heavy (Lys8/Arg8) or light (Lys0/Arg0) medium, respectively. After the 
pull-down, beads were mixed 1:1 and captured bait/prey complexes were eluted and analyzed by LC-
MS/MS. We performed in parallel a crossover experiment by label swap. Specific interaction partners 
have a heavy-to-light ratio >1 in the straight experiment and heavy-to-light ratio <1 in the crossover 
experiment, whereas unspecific binders have 1:1 heavy-to-light ratio in both experimental conditions. 
5.  DISCUSSION AND FUTURE WORK 
30 
 
We performed the SILAC based q-AP-MS analysis in quadruplicate to identify TDP43 protein 
interactors (2 straight and 2 crossover experiments). This analysis was carried out in the absence of 
RNase to identify the composition of TDP43 mRNPs. (b) Scatter plot of SILAC results. For each 
quantified protein, the SILAC intensity (y axis) and the fold change between TDP43 pull-down and 
GFP pull-down (used as negative control, x-axis) are represented. We identified 176 high-confidence 
interacting proteins (highlighted in bigger dots), with the fold-change > 1.5 and the t-test p value < 0.1. 
TDP43 interacting proteins belonging to the spliceosome (KEGG mmu03040), the ribosome (KEGG 
mmu03010), the mRNA surveillance pathway (KEGG mmu03015) and the EJC-ome (Singh et al., 
2012; 24 interacting proteins, Fold Enrichment: 15.5, Enrichment p value 1.38e-27) are highlighted in 
colours. No specific GFP-interactors were found. (c) The TDP43 interaction with the mRNA 
surveillance pathway components (UPF1, PABPC1, EIF4A3, and Y14) was validated by Western blot 
in combination with RNase A treatment. BTZ was not present in the MS-list of TDP43 interactors but 
emerged from this analysis. All interactions, except the one with PABPC1, show RNA-dependence. 
Antibody anti-HA tag was used as a control for the efficiency and specificity of TDP43 pull-down. 1.5% 
of input was loaded for each condition; the control represents NSC-34 without tagged TDP43 
expression. (d) Schematic representation of TDP43 and the members of the FET family (FUS, 
EWSR1 and TAF15). (e) The specificity of the interaction of the NMD components (UPF1, EIF4A3) 
with TDP43 in NSC-34 cell line was validated by Western blot comparing the pull-down of TDP43, 
FUS, TAF15, and EWSR1. 
  
Table 3.1 TDP43 protein interactors 
Spliceosome 
(KEGG mmu03040) 
U1 Snrnp70, Snrpa 
U2 Phf5a, Sf3a3, Sf3b2 
U4/U6 Nhp2l1 
U5 Prpf8, Snrnp200 
Sm Snrpb, Snrpd2, Snrpd3, Snrpg 
Prpl9 complex Prpf19, Hspa8, Plrg1, Cdc5l 
Prpl9 related Snw1 
EJC-TREX Acin1, Magoh, Y14, Eif4a3, Ddx39b 
hnRNPs Hnrnpa1, Hnrnpa3, Hnrnpc, Hnrnpk, Hnrnpm, Hnrnpu, Rbmxl1 
SR family Srsf1, Srsf5, Srsf6, Srsf7, Srsf10, Tra2a, Tra2b 
Ribosome 
(KEGG mmu03010) 
Small subunit 
Rps2, Rps3, Rps5, Rps8, Rps10, Rps12, Rps15a, Rps16, Rps19, Rps20, Rps21, 
Rps27, Rps27l, Rps28, Rps29, Rpsa 
Large subunit 
Rpl3, Rpl4, Rpl5, Rpl6, Rpl7, Rpl9, Rpl10a, Rpl12, Rpl13, Rpl13a, Rpl14, Rpl15, 
Rpl18, Rpl18a, Rpl19, Rpl35a, Rpl36, Rplp0, Rplp1, Rplp2 
mRNA 
surveillance 
pathway 
(KEGG mmu03015) 
EJC Acin1, Magoh, Y14, Pnn, Rnps1, Eif4a3 
Transiently 
interacting factors 
Nxf7, Ddx39b 
NMD Pabpc1, Pabpc4, Ppp2r1a, Upf1 
Exon junction 
complex-ome 
(Singh et al., 2012) 
EJC core Magoh, Y14, Eif4a3 
Peripheral EJC Acin1, Pnn, Poldip3, Rnps1 
TREX Fyttd1, Ddx39b 
hnRNPs Hnrnpc, Raly 
SR family Srrm2, Srsf1, Srsf10, Srsf6, Srsf7, Tra2a, Tra2b, Thrap3 
other mRNP Bclaf1, Erh, Ilf2, Ilf3, Matr3, Pabpc1, Pgam5 
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Others 
RNA processing 
(Biological Process, 
p value 1.082e-25) 
Chtop, Ddx1, Ddx21, Dhx9, Dkc1, Elavl1, Elavl2, Elavl4, Fbl, Gar1, Hnrnpa2b1, 
Hnrnpd, Hnrnpf, Hnrnph1, Hnrnpl, Hnrnpr, Khdrbs1, Mocs3, Mov10, Ncl, Nhp2, 
Nop10, Nop56, Nop58, Ptbp1, Rbfox2, Rpf2, Rpsa, Safb, Sf3a1, Snrnp40, Snrpb2, 
Snrpd1, Ssb, Tardbp, Ybx1 
Post-transcriptional 
gene expression 
regulation 
(Biological Process, 
p value 2.388e-16) 
Caprin1, Ddx1, Dhx9, Dkc1, Elavl1, Elavl4, Fxr1, Hnrnpa2b1, Hnrnpd, Hnrnpl, 
Hnrnpr, Igf2bp2, Igf2bp3, Khdrbs1, Mov10, Ptbp1, Pura, Serbp1, Tardbp, Ybx1, 
Ybx3 
Chromosome 
organization 
(Biological Process, p 
value 4.814e-8 ) 
Chtop, Ddx1, Dhx9, Dkc1, Fbl, Gar1, H2afv, H2afx, H2afy, Hist1h2al, Hist1h2bc, 
Hist1h3b, Hist1h4a, Hnrnpa2b1, Nhp2, Nop10, Pura, Safb, Smarca5, Top2a 
RNA binding 
(Molecular Function, 
p value 4.314e-36) 
Canx, Caprin1, Chtop, Ddx1, Ddx21, Dhx9, Dkc1, Elavl1, Elavl2, Elavl3, Elavl4, 
Fbl, Fxr1, G3bp2, Gar1, Hist1h4a, Hnrnpa2b1, Hnrnpd, Hnrnpf, Hnrnph1, Hnrnpl, 
Hnrnpr, Hnrnpul2, Igf2bp2, Igf2bp3, Khdrbs1, Mov10, Myef2, Ncl, Nhp2, Nop10, 
Nop56, Nop58, Prrc2c, Ptbp1, Pura, Rbfox2, Rpf2, Rpsa, Safb, Sec23ip, Serbp1, 
Sf3a1, Snrnp40, Snrpb2, Snrpd1, Ssb, Tardbp, Top2a, Txn, Ybx1, Ybx3 
Bag3, Banf1, Chchd3,  Cisd1, Coil, Colgalt1, Cse1l, D10Wsu52e,  Dpysl3,  Gm17669, Gnb2l1, Hist3h2ba, 
Hsph1, Lmna, Map1b,  Ott, Prdx2, Prdx4, S100a6, Sf3b14, Slc25a1, Tecr, Tmpo, Vdac3, Ywhaq 
 
3.2 TDP43 ENHANCES mRNA DEGRADATION BY A TRANSLATION-
DEPENDENT MECHANISM THAT REQUIRES SMG1 ACTIVITY 
 
Based on our finding that TDP43 binds to several components of the mRNA 
surveillance pathway, in particular, the nonsense-mediated mRNA decay, we 
investigated whether TDP43 could have a role in this process using a tethering 
assay performed in HeLa cells. The protein of interest fused to the bacteriophage 
MS2 coat protein is co-expressed with a mRNA reporter containing tandem RNA 
stem-loop MS2 binding sites in the 3’UTR, more than 50 nucleotides downstream of 
the normal termination codon. The protein function on the stability of the reporter 
can, therefore, be analyzed by directing it to a position functionally effective for NMD, 
potentially leading to a decrease of the reporter mRNA level (Figure 3.2a). 
Glutathione S-transferase (GST), a NMD-unrelated protein, is used as a negative 
control of the experiment. Y14, a component of the EJC, serves as a positive control 
since its presence downstream of the stop codon induces the assembly or the 
recruitment of the EJC and triggers NMD. As shown by Northern blot analysis, 
TDP43 tethering to the 3’UTR of the β-globin reporter reduces its mRNA abundance 
at the steady-state level (Figure 3.2b). This result is consistent with the hypothesis 
that TDP43 could be involved in the NMD pathway. To obtain a confirmation of this 
effect and a characterization of the mechanism, we combined the tethering assay 
with cycloheximide treatment obtaining a stabilization of the reporter, which 
demonstrates that the observed effect upon TDP43 tethering is translation-
dependent (Figure 3.2c). Furthermore, both the silencing of SMG1, the kinase 
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necessary for UPF1 phosphorylation to trigger NMD, and its pharmacological 
inhibition through caffeine counteracted TDP43-mediated decrease of the reporter 
mRNA (Figure 3.2d and e). We can observe that the drug treatments have a 
stronger effect on the NMD pathway inhibition than gene silencing. However, the 
knockdown approach allows identifying the involvement of specific proteins in the 
mechanism, avoiding secondary spurious effects of the drugs. Our results suggest 
that TDP43 promotes the reduction of the β-globin mRNA by a translation- and 
SMG1-dependent process.  
 
Figure 3.2 Tethered TDP43 in the 3’UTR reduces mRNA abundance by a translation-dependent 
mechanism involving SMG1 activity. (a) Schematic representation of the tethering assay performed 
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in HeLa cells. The protein of interest fused to the MS2 bacteriophage coat protein (MS2-cp) is brought 
to the 3’UTR of β-globin derived reporter mRNA harboring four MS2 binding sites (MS2-bs). An 
elongated human β-globin gene (wt+300+e3) without the MS2 binding sites serves as a control of the 
transfection efficiency. If the tethered protein nucleates the formation of an active NMD complex, the 
reporter is degraded. NMD is a translation-dependent mechanism, and UPF1 phosphorylation is 
necessary for its activation. NMD inhibition can be achieved by cycloheximide treatment or blocking 
SMG1 activity. (b) Northern blot (NB, upper panel) of MS2-V5 TDP43 tethering to the MS2 binding 
sites in the β-globin 3’UTR. MS2-V5 GST and MS2-V5 Y14 tethering were used as negative and 
positive controls, respectively. Western Blot analysis (WB, bottom panel) evidences the expression of 
the fusion proteins with the expected sizes, using the antibody anti-V5 tag. ACTININ served as protein 
loading control. Northern blots of the tethering assays in combination with (c) cycloheximide 
treatment, (d, upper panel) SMG1 knockdown and (e) caffeine treatment. Western blot confirmed the 
SMG1 silencing efficiency; TUBULIN served as protein loading control (d, bottom panel). Mean values 
of relative mRNA level with standard deviations from three independent replicates are indicated. Fold 
change of treatment/ control is indicated. Paired t-test was performed (* = p value < 0.05; ** = p value 
< 0.01; *** = p value < 0.001). 
 
3.3 TDP43 IS A TRANSCRIPT SPECIFIC NMD ENHANCER 
 
These results drove us to examine whether TDP43 is a universal player in NMD 
pathway, irrespective of its localization on target mRNAs. We employed a well-
characterized NMD reporter system composed of the β-globin pre-mRNA and a 
mutant form of it. In the mutant reporter, a nonsense mutation in the second exon 
generates a premature termination codon (PTC) after splicing (Figure 3.3a). The 
PTC-containing β-globin mRNA has been verified to be a bona fide mRNA target for 
NMD (Zhang et al., 1998). Moreover, in the 3’UTR of the wild type and the mutant 
reporter, XRN1-resistant RNA structures (xrRNA) were inserted to monitor the 5’-3’ 
mRNA degradation by the exoribonuclease XRN1, which occurs during NMD 
(Boehm et al., 2016). The presence of xrRNA protects the downstream sequence 
from degradation and produces a XRN1-resistant decay RNA fragment (xrFrag), 
which is used as a readout for 5’-3’ reporter degradation (Figure 3.3b). The 
expression of stably integrated wild type (WT) or mutant (PTC) β-globin reporters 
was induced in HeLa cells after TDP43 down-regulation by siRNA. Silencing of 
SMG1 and luciferase were used as a positive and negative control, respectively 
(Figure 3.3c). As expected, the presence of the PTC results in a strong reduction of 
the steady state mRNA level and an accumulation of xrFrag. The depletion of SMG1, 
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the kinase involved in UPF1 phosphorylation and NMD activation, leads to the 
stabilization of the full-length β-globin PTC reporter and a decrease in the level of the 
decay fragment. On the contrary, TDP43 is not required for the degradation of a 
general nonsense-containing mRNA through NMD, since its knockdown does not 
alter the ratio between the xrFrag and the full-length reporter mRNA. 
 
Figure 3.3 TDP43 silencing does not affect NMD. (a) Schematic representation of the β-globin 
xrRNA reporters. The β-globin gene contains three exons, represented as white boxes. The positions 
of the normal stop codon (STOP) and the premature termination codon (PTC) are shown. Radioactive 
probe binding sites in the 3’UTR are depicted as light gray boxes, and xrRNA structures are shown in 
red. (b) 5’-3’ mRNA degradation by XRN1 is prevented from further progression by XRN1-resistant 
RNA structure (xrRNA). The remaining RNA fragment (xrFrag) is protected from degradation and still 
contains the probe binding sites for Northern blot detection. (c) HeLa Flp-In T-REx cells were 
transfected with the indicated siRNA 48h before induction of the β-globin reporter expression with 1 
μg/mL doxycycline for 24h. Total RNA was extracted and analyzed by Northern blot (NB; left panel). 
The slower-migrating band corresponds to the full-length reporter, whereas the faster-migrating band 
is due to the xrFrag. 7SL RNA was used as endogenous control RNA. Mean values of reporter and 
xrFrag signals from three independent replicates were quantified and normalized to the WT control; 
standard deviations are shown. The ratio of xrFrag to reporter mRNA level is indicated below the 
graph. The siRNA knockdown efficiency of TDP43 and SMG1 was analyzed by Western Blot (WB; 
right panels). TUBULIN served as protein loading control. 
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3.4 TDP43 DEPLETION UP-REGULATES TARGETED mRNAs WITH 
LONG 3’UTR 
 
Taken together, the previous observations highlight that TDP43 enhances mRNA 
decay when tethered in the 3’UTR of a reporter mRNA through a translation- and 
SMG1-dependent mechanism, but it is not required for general NMD activity. This 
suggests a target-specific function for the NMD promoting activity of TDP43. We, 
therefore, focused on the identification of mRNAs controlled by TDP43 through this 
novel biological function, which could also be deregulated in TDP43-related 
pathogenesis. Since we propose TDP43 as a positive NMD regulator, the mRNA 
level of the TDP43 targets should increase upon TDP43 knockdown. We silenced 
TDP43 in the NSC-34 cell line and performed a high-throughput RNA-seq analysis. 
In the TDP43 knocked-down cells 378 up-regulated and 404 down-regulated 
transcripts were identified (Figure 3.4a). 
We compared our dataset of up regulated genes with other available sequencing 
data and a functional annotation enrichment analysis (Figure 3.4b) pointed out the 
presence of genes involved in neuron apoptosis and autophagy regulation. 
Moreover, some of them were found to be increased in ALS-induced pluripotent 
stem cells-derived neurons, in ALS samples, and in other TDP43 knockdown 
experiments, confirming the reliability of our experiment. 
Sequence analysis of differentially expressed RNAs upon siTDP43 revealed a 
significant increase in the average 3’UTR size for up-regulated transcripts (more 
than two-fold) compared to transcripts with unaffected expression levels (Figure 
3.4c). The overlap with a published catalog of TDP43 binding sites in the mouse 
brain by HITS-CLIP (Polymenidou et al., 2011) revealed a specific enrichment of 
TDP43 binding sites located in the 3’UTR region of the up-regulated transcripts 
(Figure 3.4d). Prompted by this evidence, we selected a subset of up-regulated 
transcripts reported to be bound by TDP43 in their 3’UTR, and we confirmed the 
TDP43 binding by RNA immunoprecipitation (RIP), demonstrating that the CLIP data 
from mouse brain were validated in our cell model (Figure 3.4e). 
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Figure 3.4 Analysis and characterization of transcripts altered upon TDP43 silencing. (a) 
Number of differentially expressed genes obtained upon TDP43 silencing in NSC-34 cell line. (b) 
Functional annotation enrichment analysis of up-regulated genes performed with the clusterProfiler 
Bioconductor package and the enrichR web server (10.1093/nar/gkw377, 
http://amp.pharm.mssm.edu/Enrichr/). (c) Sequence length analysis of 5’UTR, coding sequence 
(CDS) and 3’UTR of up-regulated transcripts (UP), down-regulated transcripts (DOWN) and 
transcripts without a change in their expression level (INV). Differences in 5'UTR/CDS/3'UTR length 
distributions were tested with the Wilcoxon Rank Sum Test. (d) Custom enrichment analysis of 
experimental TDP43 binfing sites in the three populations of transcripts was performed with Fisher 
test, using a published catologue of TDP43 binding sites in the mouse brain by HITS-CLIP 
(Polymenidou et al., 2011). (e) RNA immunoprecipitation analysis (RIP) of His-HA TDP43 in NSC-34. 
A subset of transcripts already published as TDP43 mRNA targets was significantly enriched in 
TDP43 immunoprecipitation compared with the control (NSC-34 without tagged TDP43 expression). 
The mRNA level was measured by RT-qPCR and normalized to Rpl10a. Fold enrichment was 
calculated versus the 5% input in three replicates. The binding of Tdp43 transcript was used as a 
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positive control of the experiment. Western blot (top panel) was used to validate the efficiency and 
specificity of TDP43 pull-down. 
 
We finally focused on Atg12, whose mRNA has been already reported as a 
conserved NMD target, in both mouse embryonic stem cells (Hurt et al., 2013) and 
yeast (Mendell et al., 2004). Atg12 mRNA is bound by TDP43 in our motor neuron-
like cells (Figure 3.5a). To confirm that Atg12 is an NMD target in our cell model, 
UPF1 silencing, as well as treatment with cycloheximide and caffeine, was 
performed. Interestingly, TDP43 down-regulation resulted in a similar increase of the 
Atg12 mRNA to that obtained by siRNA-mediated inactivation of NMD, considering 
the different knockdown efficiency of the two genes. As previously observed, the 
caffeine and cycloheximide treatment resulted in a more pronounced up regulation of 
the transcript level, showing how the pharmacological treatment determines a 
stronger inhibition of NMD, compared to the silencing approach (Figure 3.5b). 
Therefore, this evidence prompts us to conclude that Atg12 is targeted by NMD in 
NSC-34 cells, and TDP43 is involved in the regulation of its expression. 
 
Figure 3.5 Analysis of TDP43 and NMD effects on the Atg12 transcript. (a) RNA 
immunoprecipitation analysis (RIP) of His-HA TDP43 in NSC-34. Atg12 mRNA was significantly 
enriched in TDP43 immunoprecipitation compared with the control (NSC-34 without tagged TDP43 
expression).  mRNA level was measured by RT-qPCR and normalized to Rpl10a. Fold enrichment 
was calculated versus the 5% input. The binding of Tdp43 transcript was used as a positive control of 
the experiment. Paired t-test was performed (* = p value < 0.05; ** = p value < 0.01; n = 3). (b) 
Quantitative real-time PCR (qRT-PCR) analysis of Atg12 expression level when TDP43 or UPF1 are 
down-regulated, when translation is inhibited by cycloheximide treatment or when UPF1 
phosphorylation is blocked by caffeine. siRNA for luciferase was used as a control in the silencing 
experiments. The relative quantification was determined via the ΔΔCt method and normalized to the 
endogenous controls Rpl10A and Ppia. Welch’s t-test (one tail) was performed (* p value < 0.05; ** p 
value < 0.01; *** p value < 0.001, n = 4). 
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4. RESULTS: TDP43 AND ALTERNATIVE 
POLYADENYLATION 
 
4.1 ALTERNATIVE POLYADENYLATION IS ALTERED IN TDP43Q331K 
MOUSE MODEL 
 
In 2015 Prudencio and colleagues added ALS to the list of human diseases 
associated with polyadenylation sites shifts, reporting an alternative polyadenylation 
(APA) alteration in sporadic ALS cases and c9ALS patients with a repeat expansion 
in C9orf72 gene. From this evidence and supported by the fact that TDP43 can 
regulate the APA of its mRNA (Avendaño-Vázquez et al., 2012; Koyama et al., 
2016), we investigated a possible APA change in TDP43Q331K mice. This ALS mouse 
model expresses TDP43 with the ALS-linked mutation Q331K in the central nervous 
system, both in neurons and astrocytes (Figure 4.1a). It results in an age-dependent 
mild motor phenotype, not observed in TDP43wt mouse (Arnold et al., 2013). 
Measurement of TDP43 protein expression in the spinal cord of these mice revealed 
a decrease of endogenous murine protein and an enrichment of the transgenic 
TDP43, which was found to be polyubiquitinated. This feature is evident in the late-
stage of the pathology, at ten months of age (Figure 4.1b). We performed a 
behavioral characterization of this mouse model, assessing the motor deficit at 
different time points during the development of the disease. We tested the motor 
performance and the coordination skills by accelerating rotarod test. In our hands, 
this model develops a mild but significant motor deficit at early-stage (two months) in 
comparison with littermate mice, with a worsening of the performance during disease 
progression (Figure 4.1c). We attribute the decreased latency to fall observed in the 
non-transgenic mice at ten months to aging. An abnormal hind limb clasping is 
visible in 6-month-old TDP43Q331K mice, but not in non-transgenic littermate mice 
(Figure 4.1d). 
4.  RESULTS: TDP43 AND ALTERNATIVE POLYADENYLATION 
39 
 
 
Figure 4.1 TDP43Q331K mouse model. (a) Representation of the transgene expressed in the mouse 
model (B6N.Cg-Tg(Prnp-TARDBP*Q331K)103Dwc/J). The Myc-tagged human TDP43 carrying the 
ALS-linked Q331K mutation is directed to the brain and the spinal cord by the mouse prion protein 
promoter. Below, the mice breeding scheme is depicted. (b) Western blot analysis of the proteins 
extracted with Trizol from the spinal cord of three non-transgenic and three transgenic TDP43Q331K 
mice at three and ten months of age. The antibody anti-TDP43 can recognize both the murine and the 
tagged human protein. At ten months the transgenic mice show a smear due to the polyubiquitination 
of TDP43. TUBULIN was used as a loading control. (c) Accelerating rotarod test performed on 
transgenic and littermate mice from two to ten months of age. TDP-43Q331K mice displayed a 
significant impairment in motor performance and a lower latency to fall, compared to non-transgenic 
mice (* = p value < 0.05; ** = p value < 0.01). (d) Hind limb clasping tested at six months of age. 
 
We sequenced the 3’ end of polyadenylated RNAs extracted from spinal cords of 
ALS and littermate mice at three and ten months of age (Figure 4.2a). We 
considered the reads with 3’ end mapping within 10bp from the transcript end 
(median 12 million reads, minimum 7 million, maximum  21 million), which represent 
the 95% of the signal (Figure 4.2b). 
Among the detected polyadenylation sites, over 3000 genes (23.4%) have more than 
one PAS (Figure 4.2c). The same sequencing approach was previously used in 
HEK293 cells, where 3291 genes were annotated with multiple poly(A) sites (Rot et 
al., 2017). 
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Figure 4.2 Analysis of APA in spinal cords of TDP43Q331K transgenic and non-transgenic mice. 
(a) Experimental design and pipeline of QuantSeq Reverse 3’ mRNA-Seq library preparation  
(Lexogen), which allows mapping the sequences close to the 3’ end of polyadenylated RNAs at 
nucleotide resolution. We analyzed three mice for each condition. (b) Metaprofile plot of read-end 
sites distribution respect to known polyadenylation sites. From the quality control of 3’end analysis, 
95% of the signal maps in a window of 10 nucleotides before the polyadenylation site (3 nucleotides 
of dispersion is allowed). The reads outside this region were not considered, excluding the false 
positives due to oligodT priming in sequences with long A-stretches. (c) Distribution of the number of 
detected PA sites per gene, considering all the classes of APA events (see Paragraph 1.4.2). 
 
Our analysis showed a shift in the PAS selection, comparing the non-transgenic 
mice at ten and three months. Specifically, the process of aging is followed by 
preference in proximal PAS selection and the consequent production of shorter 
isoforms (Figure 4.3a). Previously, other biological processes were linked with broad 
APA modulation, as development, proliferation and neuron activity (Elkon et al., 
2013), since this mechanism controls the gene expression. 
Moreover, concerning the results from the transgenic mouse model, our study 
revealed an increase of differentially polyadenylated genes (DPGs) with the 
pathology progression. At the late-stage of the disease, ~20% of the genes 
characterized by the presence of more than one PAS have a different 3’ end (Figure 
4.3b). Examining the two alternative polyadenylation events (tandem or splicing-
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dependent) separately, we didn’t find an enrichment in one of the two classes among 
the differentially polyadenylated genes. The percentage of tandem APA with 
differential usage is 20% at three months and 34% at 10 months, considering a 36% 
of background, which represents the number of genes with more than one PAS 
because of a splicing-independent event. The analysis of the transcripts with a shift 
in the PAS usage revealed an enrichment in genes altered in ALS (Figure 4.3c).  
 
 
Figure 4.3 APA is altered during aging and ALS progression (a) Defining pAu as the 
polyadenylation site usage, quantified according to the number of reads, we calculated for the 
proximal (PROX) and the distal (DIST) polyadenylation site (PAS) the delta pAu as pAu (non-
transgenic mouse ten months of age) - pAu (non-transgenic mouse three months of age). An example 
is reported.  APA changes in non-transgenic mice comparing the two ages are shown in the bottom 
panel. (b) Number of differentially polyadenylated genes (DPGs) with two or more alternative 
polyadenylation sites in TDP43Q331K transgenic mice at three and ten months of age and (c) their 
functional annotation enrichment analysis performed with the clusterProfiler Bioconductor package 
and the enrichR web server.  
 
4.2 TDP43 MODULATES ALTERNATIVE POLYADENYLATION, 
PROMOTING THE PROXIMAL PAS USAGE OF ITS TARGETS 
 
To study the molecular mechanism through which TDP43 modulates the alternative 
polyadenylation at the genome wide level, we performed 3’ end sequencing of NSC-
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34 cells knocked-down for TDP43. We identified 417 differentially polyadenylated 
genes (Figure 4.4a), involved in RNA processing and nervous system development 
(Figure 4.4b). Interestingly, analyzing the DPGs, we observed a statistically 
significant preference in the usage of the distal PAS when TDP43 is silenced (Figure 
4.4c). This result suggests an involvement of TDP43 in the modulation of APA of a 
subset of transcripts. 
 
 
Figure 4.4 TDP43 depletion induces a shift in the polyadenylation site usage. (a) Scatter plot of 
differentially polyadenylated genes (DPGs) in NSC-34 cell line down-regulated for TDP43 and (b) the 
relative gene ontology (GO) analysis (BP, Biological Process; CC, Cellular Compartment, Molecular 
Function). (c) According to the number of reads, we quantified pAu for each DPG and calculated for 
the proximal (PROX) and the distal (DIST) polyadenylation site (PAS) the delta pAu as pAu (siTDP43) 
- pAu (siCTRL). An example is reported. We used siRNA for luciferase as a silencing control 
(siCTRL), conducting the experiment in duplicate. The bottom panel shows the delta pAu of DPGs in 
NSC-34 silenced for TDP43. 
 
To find a functional model for TDP43, we crossed our sequencing data with the 
positional information of the TDP43 binding sites coming from published murine 
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brain HITS-CLIP data (Polymenidou et al., 2011). TDP43 depletion is known to be 
accompanied by alterations in alternative splicing (Xiao et al., 2011; Tollervey et al., 
2011) and in cryptic splice site suppression (Ling et al., 2015). Therefore, we 
focused our analysis on significant tandem APA events to exclude an effect due to 
splicing involvement (Figure 4.5a). The percentage of DPGs produced by tandem 
APA is 37%, with a background of 36% as previously explained. From our analysis 
22 known TDP43 targets emerged differentially polyadenylated in silenced NSC-34 
cells and the position of the binding site turns out to be between the proximal and the 
distal PAS for all of them (Figure 4.5b). The Gene Ontology analysis revealed the 
presence of genes involved in cell differentiation, synapse organization and nervous 
system development (Figure 4.5c).  
 
Figure 4.5 TDP43 promotes the proximal PAS usage of its mRNA targets (a) Pie chart 
representing the APA classes (tandem and splicing-dependent) of DPGs in NSC-34 cell line silenced 
for TDP43. An APA event is tandem when produces transcripts with the same start coordinate of the 
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last exon; otherwise, it is splicing-dependent. We crossed the genes characterized by a differential 
tandem APA, with a catalog of 75000 TDP43 binding sites in the mouse brain by HITS-CLIP 
(Polymenidou et al., 2011). The box whisker plot shows the delta pAu of DPGs in NSC-34 silenced for 
TDP43 produced by a tandem APA event and bound by TDP43. For all the genes, the binding site of 
TDP43 is between the proximal (PROX) and distal (DIST) PAS. The first 11 genes are listed on the 
right. (c) Gene ontology (GO) analysis showing the enriched Biological Processes (BP), Cellular 
Compartments (CC) and Molecular Functions (MF). (d) Representation of the different 3’ ends of 
Ube2v2 and the TDP43 binding site. The pAu of each transcript calculated from the sequencing data 
is indicated in the graphs below. 
 
We validated our sequencing data by real-time PCR focusing our attention on 
Ube2v2, one of the genes most differentially polyadenylated (Figure 4.5d). Using 
pairs of primers suitably designed to amplify the transcript with the long 3’UTR or to 
quantify the total expression level of the gene (Figure 4.6a), we confirmed that the 
distal PAS of Ube2v2 is preferred in TDP43 silenced NSC-34 cells (Figure 4.6b and 
c). We further verified that TDP43 binds the long isoform of Ube2v2 in our cells 
(Figure 4.6d). 
 
 
Figure 4.6 Validation of TDP43 effect on alternative polyadenylation of Ube2v2 transcript. (a) 
The two possible 3’ ends of Ube2v2 are represented. The yellow arrows indicate the specific primers 
for the transcript with a long 3’UTR (Ube2v2-001); the red primers map on both transcripts (Ube2v2-
001 and -002) and were used to quantify the total expression level of the gene. (b) Quantitative real-
time PCR (qRT-PCR) analysis of Ube2v2 expression level upon TDP43 silencing. siRNA for 
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luciferase was used as a silencing control (siCTRL). The relative quantification was determined via 
the ΔΔCt method and normalized to the endogenous controls Rpl10a and Ppia. Paired t-test was 
performed on 3 biological replicates (** = p value < 0.01). (c) Quantification of the delta pAu of 
Ube2v2 in NSC-34 silenced for TDP43. Paired t-test was performed on 3 biological replicates (* = p 
value < 0.05) (d) RNA immunoprecipitation analysis (RIP) of His-HA TDP43. Ube2v2 mRNA was 
significantly enriched in TDP43 immunoprecipitation compared with the control (NSC-34 without 
tagged TDP43 expression). mRNA level was measured by RT-qPCR using the primers for the 
transcript with a long 3’UTR (Ube2v2-001; yellow primers in (a) ) and normalized to Rpl10a. Fold 
enrichment was calculated versus the 5% input. The binding of TDP43 transcript was used as a 
positive control of the experiment. Paired t-test was performed (** = p value < 0.01; n = 3). 
 
To confirm the role of TDP43 in alternative polyadenylation and to study the 
positional effects in the regulation of the PAS selection, we performed a tethering 
assay using a β-globin reporter, presenting 4MS2 binding sites in the 3’UTR between 
the cryptic proximal and the distal polyadenylation sites (Figure 4.7a). When the 
negative control GST is tethered, the distal PAS is used, since its sequence is 
stronger than the proximal one. The tethering of TDP43 and CSTF1, a component of 
the core polyadenylation machinery used as a positive control, reverses this 
situation. Both proteins promote the production of a shorter form of the reporter that 
can be distinguished by Northern blot analysis (Figure 4.7b). Moreover, we tested 
that TDP overexpression does not affect the β-globin transcript when it is not 
tethered (Figure 4.7c). 
The 3’ end processing occurs co-transcriptionally in the nuclear compartment. 
Performing a nucleus-cytoplasm fractionation of the transfected cells, we showed 
that the short isoform of the β-globin produced by the tethering of TDP43 and CSTF1 
is present in both cellular fractions (Figure 4.7d). 
The cryptic PAS mutagenesis converted the APA reporter (β-globin 4MS2 APA) in 
an NMD target (β-globin 4MS2 Δproximal PAS) when TDP43 is tetherd since the 
MS2 binding sites are located >50 nucleotides downstream the stop codon (Figure 
4.7e). Y14 is not involved in the processing of the 3’ end and, therefore, induces the 
degradation of both reporters. On the contrary, TDP43 plays a role in APA 
enhancing the 3’UTR cleavage upstream its binding site. In the absence of the 
proximal PAS, the MS2 binding sites are not removed and TDP43 can mediate the 
reporter decay through a post-transcriptional process. 
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Figure 4.7 Validation of TDP43 involvement in alternative polyadenylation with a reporter assay 
(a) Schematic representation of the β-globin reporters used in the tethering assay performed in HeLa 
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cells. 4 MS2 binding sites are located in the 3’UTR of the β-globin reporter, between its proximal and 
distal polyadenylation sites (β-globin 4MS2 APA). When a protein involved in APA is tethered in that 
region, it causes the production of a shorter reporter (β-globin short). β-globin 4MS2 Δproximal PAS 
was obtained by PCR site-directed mutagenesis of the proximal PAS and used in figure 4.7e. (b) 
Northern blot of TDP43 tethered between the proximal and the distal polyadenylation sites of the 
reporter β-globin 4MS2 APA. GST and CSTF1 tethering were used as negative and positive controls, 
respectively. An elongated human β-globin gene (β-globin 300+e3) without the MS2 binding sites 
served as a control for transfection efficiency. Western blot (bottom panel) validates the expression of 
the tethered V5 tagged proteins. ACTININ was used as a protein loading control. (c) Northern blot of 
His-HA and MS2-V5-TDP43 overexpression effect on β-globin 4MS2 APA . MS2-V5-GST is used as a 
control. Western blot (bottom panel) validates the expression of the tagged proteins (indicated by ◄) 
by using an antibody anti-TDP43. (d) Northern blot of tethering experiment performed with the β-
globin 4MS2 APA reporter, after nucleus-cytoplasm fractionation. 7SL RNA marks specifically the 
cytoplasmic fraction (C) and is not detectable in the nuclear fraction (N). Western blot (bottom panel) 
validates the expression of the tethered V5 tagged proteins and the nucleus/cytoplasm fractionation. 
GAPDH and Histone 3 (H3) were used as cytoplasmic and nuclear markers, respectively. (e)  
Northern blot of TDP43 tethering performed with the β-globin 4MS2 APA and the β-globin 4MS2 
Δproximal PAS.  
 
4.3 ALS-LINKED Q331K MUTATION DOES NOT ALTER THE TDP43 
EFFECT ON APA AND NMD 
 
To investigate if the presence of Q331K point mutation in the C-terminal domain of 
TDP43 can alter its novel functions, we repeated the previous tethering assays on 
APA and NMD reporters. From the Northern blot data, we observed that the mutant 
is still able to influence the choice of the polyadenylation site (Figure 4.8a) and to 
degrade the reporter (Figure 4.8b). However, the expression of TDP43Q331K for 48h 
in NSC-34 does not produce cytoplasmic aggregates (Figure 4.8c). 
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Figure 4.8 TDP43 Q331K is still able to affect the APA and NMD reporters. (a) Northern blot of 
TDP43 wt and Q331K tethered to (a) the β-globin 4MS2 APA and (b) the β-globin 4MS2 Δproximal 
PAS. In both experiments, β-globin 300+e3 served as a control for transfection efficiency. GST 
represents the negative control; CSTF1 and Y14 are used as positive controls of the two experiments. 
Western blots (bottom panels) show the expression level of the tethered V5 tagged proteins. ACTININ 
was used as a protein loading control. (c) Representative images of NSC-34 expressing TDP43 wt or 
TDP43Q331K. Antibody anti-PABPC1 is used as a marker of stress granules. The objective used for 
image acquisition was PlanApo oil immersion lens 63x/1.4. 
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4.4 THE GLYCINE-RICH DOMAIN OF TDP43 MEDIATES THE 
INTERACTION WITH THE CSTF COMPLEX AND THE TDP43 
ACTIVITY IN ALTERNATIVE POLYADENYLATION REGULATION 
 
We demonstrated by immunoprecipitation the direct interaction of TDP43 with the 
CSTF1 and CSTF3 components of the CSTF complex in the NSC-34 cell line 
(Figure 4.9a). We obtained the same outcome repeating the experiment in HeLa 
cells (data not shown). In both cases the interaction was found to be RNA-
independent. This result is also supported by the interaction of TDP43 W113A-
R151A with the complex (Figure 4.9d). These point mutations were reported to 
decrease the binding of TDP43 to UG repeats (Ayala et al., 2005; Ihara et al., 2013). 
As a further demonstration of this binding, we proved the TDP43 interaction with 
mVenus-CSTF1 (Figure 4.9b). 
Using a truncated form of TDP43 lacking the glycine-rich C-terminal part (Figure 
4.9c), we demonstrated that this domain is necessary for the interaction with CSTF1 
(Figure 4.9d). Its absence causes a consistent reduction in proximal polyadenylation 
site selection (Figure 4.9e), without altering the nuclear localization of the protein 
(Figure 4.9f). 
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Figure 4.9 TDP43 interacts directly with the CSTF complex. (a) The interaction of TDP43 with 
CSTF1 and CSTF3 in NSC-34 cell line was proved by immunoprecipitation coupled with Western blot 
analysis in combination with RNase A treatment. 1.5% of input was loaded for each condition; the 
control represents NSC-34 without tagged protein expression. Antibody anti-HA tag was used as a 
control for the efficiency and specificity of TDP43 pull-down. * indicates the heavy chain of the IgG. 
RNA extracted from the flow through and run onto 1.5% agarose gel demonstrates the RNA 
degradation due to RNase A treatment (bottom panel). (b) We further confirmed the interaction of 
TDP43 with CSTF1 by immunoprecipitation coupled with Western blot analysis co-transfecting HeLa 
cells with His-HA TDP43 and mVenus CSTF1. Antibody anti-GFP was used to detect the tagged 
CSTF1. (c) Schematic representation of TDP43 wt and TDP43 ΔC-term, the fragment without the 
glycine-rich C-terminal part. (d) TDP43 wt, TDP43 W113A-R151A and TDP43 ΔC-term 
immunoprecipitation coupled with Western blot analysis in NSC-34 cells. (e) Northern blot of TDP43 
wt and ΔC-term tethered between the proximal and the distal polyadenylation sites of the reporter β-
globin 4MS2 APA. β-globin short is the short isoform produced by alternative polyadenylation. GST 
and CSTF1 tethering were used as negative and positive controls, respectively. An elongated human 
β-globin gene (β-globin 300+e3) without the MS2 binding sites served as a control for transfection 
efficiency. (f) Representative images of NSC-34 expressing mVenus-TDP43 wt, mVenus-TDP43 ΔC-
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term, and mVenus-CSTF1. The cells were imaged on the High Content Screening System Operetta™ 
(PerkinElmer), through which we performed the cellular localization analysis of these proteins, 
quantifying the GFP intensity in the nucleus and the cytoplasm. The nuclei were identified by Hoechst 
staining. As previously shown by Western blot of nucleus-cytoplasm fractionation (Figure 4.7d), 
overexpressed CSTF1 is more cytoplasmic than nuclear. 
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TDP43 is a mostly nuclear RNA-binding protein ubiquitously expressed and found 
accumulated in the cytoplasm in sporadic and familial ALS patients (Neumann et al., 
2006; Igaz et al., 2008). However, it is still unclear why this phenomenon, called 
TDP43 proteinopathy, causes selective motor neuron death. 
The molecular function of TDP43 has been extensively investigated in the past. As a 
result, the protein has been implicated in several processes related to control of 
gene expression: transcription regulation, mRNA splicing, transport, stability and 
translation (Buratti et al., 2001; Fiesel et al., 2009; Freibaum et al., 2010; Tollervey et 
al., 2011; Polymenidou et al., 2011; Ling et al., 2015). 
The analysis of protein-protein interactions (PPIs) is a widely used unbiased 
approach to study the role of a target protein inside the cell. It has been reported that 
more than 80% of proteins form complexes to elicit their functions (Berggård et al., 
2007), and proteins involved in the same cellular process emerge as interactors from 
PPI studies (von Mering et al., 2002). Earlier studies investigated the interacting 
proteins of TDP43, demonstrating a strong association with mRNA splicing, 
microRNA processing and translation machinery (Freibaum et al., 2010; Ling et al., 
2010; Blokhuis et al., 2016). To find out possible novel roles of TDP43, we adopted a 
SILAC-based proteomic approach for analyzing its protein interactome in NSC-34, a 
motor neuron-like cell line (Figure 3.1). The presence of known TDP43 binders in 
the list of its specific interactors, as the spliceosome and the ribosome components, 
supported the validity of our analysis. An entirely new result was the enrichment in 
several factors involved in the mRNA surveillance pathway and constituting the EJC-
ome. It is interesting to observe how these four classes could belong to the same 
pathway. In fact, the Exon Junction Complex is assembled during the pre-mRNA 
splicing, is removed by the ribosome during the first round of translation, and allows 
the recognition and the degradation of mRNAs with a premature termination codon 
by the translation-dependent mRNA surveillance pathway, in particular the EJC-
dependent Nonsense-mediated decay (Figure 5.1). 
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Figure 5.1 Enriched classes in the TDP43 protein interactome. 
 
Recently, TDP43 has been indirectly linked to NMD by the elucidation of its role in 
suppression of cryptic splicing (Ling et al., 2015). TDP43 silencing increases the 
level of mature transcripts including cryptic exons of intronic origin. Consequently, it 
raises the frequency of transcripts with a premature termination codon subjected to 
NMD. Another finding suggesting a role of TDP43 in NMD comes from a genetic 
screen in yeast, which demonstrated that a yeast homolog of hUPF1 and hUPF1 
itself prevent TDP43-mediated toxicity (Ju et al., unpublished). The overexpression 
of UPF1 counteracts TDP43 cytotoxicity in primary neuronal cultures (Barmada et 
al., 2013) and slows disease progression in an ALS model of rat (Jackson et al., 
2015). These works support the involvement of UPF1 inactivation in TDP43-induced 
motor neuron degeneration in vitro and in vivo, and possibly, therefore, in NMD, 
even if functions of UPF1 other than that of NMD effector are known (Varsally et al., 
2012). 
Moreover, NMD was shown to be involved in the synaptic morphology and function 
maintenance. The loss of a central NMD player as SMG1 (Long et al., 2010) or an 
EJC core component as EIF4A3 (Bramham et al., 2008; Giorgi et al., 2007) leads to 
NMJ synaptic architectural and functional impairments, suggesting a possible 
involvement of NMD alteration in locomotor degeneration and ALS development. 
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Our data, particularly the interaction with cytoplasmic components of the mRNA 
surveillance pathway, suggest an involvement of TDP43 in the NMD pathway, that 
we substantiated adopting a classical approach (Gehring et al., 2008; Gehring et al., 
2009). We tethered TDP43 in the 3’UTR of a β-globin reporter, in a position that 
triggers NMD. The presence of TDP43 more than 50 nucleotides downstream of the 
normal stop codon induces the reduction of the β-globin mRNA by a translation- and 
SMG1-dependent process (Figure 3.2). Moreover, we proved that TDP43 
downregulation does not generally affect the NMD machinery, suggesting that the 
effect observed by the tethering assay depends on the direct binding of TDP43 to the 
mRNA undergoing NMD (Figure 3.3). 
NMD can follow three different routes, which differ principally in their being 
dependent or not on the EJC. These alternative models are: (a) EJC-dependent 
NMD, which is activated in the presence of a premature termination codon. (b) EJC-
independent NMD, which depends on the length of the 3’UTR and the distance 
between the stop codon and PABPC1. (c) STAU1-mediated decay, where 
STAUFEN1 binds its binding sites in the 3’UTR and recruits UPF1, eliciting the 
decay of the transcript. 
Our genome-wide sequencing analysis of NSC-34 cells silenced for TDP43 (Figure 
3.4) showed that the up-regulated mRNAs are characterized by a significant 
increase in the average 3’UTR size. Moreover, the use of a published list of TDP43 
RNA interactions in the mouse brain highlighted an enrichment of its binding sites in 
the 3’UTR region of the up-regulated transcripts. 
The identification of up-regulated transcripts with a long 3’UTR, the tethering results, 
and the directed interaction with PABPC1 could suggest the involvement of TDP43 
in the EJC-independent NMD. As previously reported (Singh et al., 2008), a long 
3’UTR is an important feature of “physiological” NMD targets. TDP43, binding the 
3’UTR of its target and interacting with PABPC1, could interfere with a correct 
translation termination (Figure 5.2a). To confirm or disprove if the role of TDP43 in 
increasing NMD sensitivity of the bound mRNAs could be ascribed to its binding in 
the 3’ UTR, we will clone after the β-globin coding sequence the 3’UTR of a 
transcript targeted by TDP43, presenting or not its binding site. The positivity of this 
result could allow us to move toward the demonstration that EJC-independent NMD 
is a target of TDP43. 
On the other side, and even if it did not emerge from our SILAC-based proteomic 
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analysis, the interaction between TDP43 and STAUFEN1 has been reported in 
different studies (Yu et al., 2012; Milev et al., 2012). This raises the interesting 
possibility that they act together in favouring decay of their targets (Figure 5.2b), and 
therefore that TDP43-mediated decay and STAUFEN1-mediated decay are two 
special forms of NMD sharing a common mechanism of action. This hypothesis 
could be tested by combining the TDP43 tethering with the down-regulation of 
STAUFEN1. We could also cross our sequencing data with the binding sites not only 
of TDP43 but also STAUFEN1 to find common transcripts. 
Another possible explanation of the results obtained from our tethering experiments 
could be that TDP43, as other RBPs (Singh et al., 2012; Le Hir et al., 2016), is able 
to influence the deposition, the assembly and/or the stability of the EJC (Figure 
5.2c). To verify this option, we will combine the TDP43 tethering assay with the 
overexpression of the ribosome-associated protein PYM, which acts as an EJC 
disassembly factor (Gehring et al., 2009).  
 
Figure 5.2 Possible mechanisms of action through which TDP43 could be involved in mRNA 
decay. 
 
Even if the involved mechanism is still unclear, its impairment could play a 
pathological role in ALS. Since we propose TDP43 as an NMD enhancer, the loss of 
its function would induce an increase of its mRNA targets, and their higher 
expression could have a toxic effect on the cell. 
The up-regulated transcripts upon TDP43 silencing resulted ontologically enriched in 
autophagy and apoptosis terms. Autophagy is an essential process to neuronal 
homeostasis, and it is involved in protein degradation, organelle turnover and stress 
response (Levine and Kroemer, 2008). Its dysregulation (excessive induction or 
deficiency), due to the impairment of the autophagic flux or its regulatory processes, 
is linked to ALS but also to other neurodegenerative diseases, such as Alzheimer’s 
disease, Huntington’s disease, Parkinson’s disease and frontotemporal dementia 
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(Wong and Cuervo, 2010; Chen et al., 2012). The alteration of the autophagic 
process was previously linked to TDP43 neurodegeneration (Ying et al., 2016, Bose 
et al., 2011) and NMD pathway inhibition (Wengrod et al., 2013), highlighting a 
possible connection among these three conditions. Also, silencing of TDP43 has 
been already associated with apoptosis activation (Ayala et al., 2008). We showed 
that Atg12 is up-regulated upon TDP43 silencing and NMD inhibition (Figure 3.5). It 
codifies for an autophagic protein, which also plays a proapoptotic role, inhibiting 
members of the anti-apoptotic Bcl-2 family (Rubinstein et al., 2011). For this reason, 
alteration of the ATG12 level could have an impact on these two processes. 
To consolidate our findings and evaluate their impact on ALS, we are planning to 
perform further analysis on transcripts targeted by this novel TDP43 mechanism. We 
will evaluate the effect of enforced overexpression of validated TDP43 targets, as 
Atg12, on autophagy, apoptosis, and cell viability, using primary motor neurons and 
looking at specific markers. In this way, we will be able to propose causality between 
the impairment of NMD due to TDP43 loss, the increase of the transcripts level and 
cell features. 
We will move to an in vivo system to consolidate our findings obtained in cell culture 
and clarify the role of NMD in ALS pathogenesis. We will silence in Drosophila key 
components of the NMD machinery, such as NonC1 (the ortholog of Smg1) and 
Upf1, with a motor neuron specific driver (D42-Gal4). We will compare them to Tbph 
silencing (the ortholog of Tardbp), using a newly ALS Drosophila model established 
in our laboratory. Finally, we will assess the contribution to ALS of transcripts 
targeted by TDP43-dependent NMD in our in vitro experiments. We will silence their 
orthologs in Drosophila and evaluate the genetic interactions, the degeneration of 
the larval neuromuscular junctions, and the motor performance in the adult. 
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In the second session of this project, we showed that alternative polyadenylation 
changes with the aging and its alteration increases during the disease progression in 
the spinal cord of an ALS mouse model (Figure 4.3), where TDP43Q331K is 
overexpressed causing an age-dependent mild motor phenotype (Figure 4.1). 
We demonstrated by 3’end sequencing analysis of NSC-34 silenced for TDP43 and 
the use of a specific reporter, a novel mechanism through which this protein could 
modulate alternative polyadenylation, promoting the production of shorter transcripts. 
Our sequencing data identified 417 genes differentially polyadenylated upon TDP43 
silencing in neuronal cells. Among them, we observed a shift in the usage of the 
polyadenylation site, with a significant preference in the selection of the proximal 
PAS (Figure 4.4). This feature resulted much more evident analyzing only the 
tandem events (Figure 4.5). Since TDP43 is involved in alternative splicing 
regulation, excluding from the analysis the transcripts subjected to splicing 
dependent-APA, we reduced the possible involvement of other mechanisms.  
Using the published TDP43 RNA interactome from mouse brain (Polymenidou et al., 
2011), we found that TDP43 binds between the proximal and the distal PAS of all of 
its identified targets. The low number of genes (22) obtained crossing the two 
datasets could be ascribed to an intrinsic feature of the mechanism. Indeed, if 
TDP43 really promotes the usage of the proximal PAS, the longest isoform of the 
transcript will be less abundant, and therefore the TDP43 signal between the two 
PASs in these tandem transcripts will suffer a representation bias with respect to the 
other TDP43 binding sites. To provide a more consistent map of TDP43 binding sites 
to test our model, we are planning to perform iCLIP of endogenous TDP43 in our 
cells. 
We demonstrated by a tethering experiment (Figure 4.7), how this protein could 
modulate alternative polyadenylation. We used a β-globin reporter presenting a 
cryptic proximal PAS (AUUAAA) and a distal PAS with a strong sequence 
(AAUAAA), which is usually preferred. Upon transfection, it leads to the expression 
of a long isoform predominantly (Figure 5.3a). As observed from our sequencing 
data, when TDP43 is tethered between the proximal and the distal PAS, it leads to 
the usage of the upstream PAS and the production of a shorter isoform (Figure 
5.3b). This outcome suggests the TDP43 involvement in the promotion of the 
proximal polyadenylation site and/or the repression of the distal one. To identify the 
effective role of TDP43, we removed the cryptic sequence by mutagenesis (Figure 
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5.3c). Since, in this way, the MS2 binding sites are located more than 50 nucleotides 
after the stop codon, we obtained a TDP43-mediated decay sensitive reporter, which 
generates a long isoform when NMD is downregulated. However, the treatments 
resulted in having a lower effect on the tethering of TDP43, than that of Y14, a core 
component of the EJC (Figure 3.2).  This observation leads us to suppose that 
TDP43 could enhance the upstream PAS selection, but also partially repress the 
downstream site usage, preventing the complete maturation of the transcript when 
the cryptic site is absent. The correctly processed mRNAs are transported from the 
nucleus to the cytoplasm, where they undergo NMD. 
We can hypothesize to apply other modifications to the reporter to have more 
evidence about the positional effect of TDP43 in alternative polyadenylation 
modulation. Deletion of the distal PAS (Figure 5.3d) and TDP43 tethering 
downstream the distal PAS (Figure 5.3e) would not provide us more information on 
the mechanism. However, we could move the MS2 binding sites upstream the 
weaker PAS (Figure 5.3f) to obtain a reporter less sensitive to distal site inhibition 
and more suitable for NMD studies. 
 
Figure 5.3 Different uses of the tethering approach to study how TDP43 modulates APA. 
 
Our results obtained from the tethering experiments are supported by a recent study. 
Rot and co-workers integrated iCLIP and 3’ mRNA sequencing data performed in 
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HEK293 cells. They found that TDP43 can bind upstream (40-80 nucleotides before 
the PAS) or near the proximal PAS (from 40 nucleotides before to 20 nucleotides 
after the PAS), preventing its selection and indirectly promoting the use of the distal 
site. They showed that TDP43 can also enhance the selection of the proximal site 
binding downstream sequences (20-80 nucleotides after the PAS). In their work a 
position-dependent regulatiory principle is presented, however they did not provide a 
demonstration of the involved mechanism.  
Polyadenylation of the mRNA is a two-step reaction and needs the involvement of 
multiple cis- and trans-acting factors. The heterotrimer CSTF acts during the 
endonucleolytic cleavage and determines the polyadenylation efficiency. In 2009 Shi 
and co-workers purified and analyzed the protein composition of the human mRNA 3′ 
processing complexes, identifying a direct association with TDP43. In 2014 Costessi 
and colleagues failed to demonstrate the interaction between TDP43 and CSTF2, 
the member of the CSTF complex involved in the RNA-binding, rejecting the possible 
involvement of TDP43 in the regulation of polyA tail length. We were also unable to 
show this interaction, but we observed that TDP43 directly binds to the other two 
components of the CSTF complex (CSTF1 and CSTF3, Figure 4.9). The cause 
could be that, for technical reasons (e.g. buffer composition, antibody sensitivity), the 
interaction with CSTF2 cannot be detected. Another possibility could be that TDP43, 
which has the same binding site of CSTF2 (UG-stretches), forms a novel complex 
with CSTF1 and CSTF3 (the active components of the CSTF complex), which does 
not include component 2. We did not detect the CSFT complex in our SILAC based 
proteomic analysis of the TDP43 interactome, and this also occurred for the 
identification of TDP43 interaction with Barentsz (Figure 3.1 and Table 3.1). 
Ionization biases and peptide mapping failures can be a common source of false 
negatives in protein identification by mass spectrometry. These proteins are absent 
in the list of specific TDP43 interactors, but also among the unspecific binders, so 
this would possibly mean that they were left out by the analysis. For this reason, we 
directly interrogated the TDP43 immunoprecipitation by Western blot. The 
combination of these high- and low-throughput proteomic approaches allowed us to 
circumvent their respective disadvantages. 
The disease-related form of TDP43 is hyperphosphorylated, polyubiquitinated, and 
cleaved before the C-terminal domain (Neumann et al., 2006; Igaz et al., 2008). This 
region is also characterized by the presence of the most ALS-linked mutations 
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(Pesiridis et al., 2009) and is involved in several protein-protein interactions (Buratti 
et al., 2005; Ayala et al., 2005). From our analysis, the ALS-linked Q331K mutation 
does not affect the TDP43 functions and, as previously observed (Ling et al., 2010), 
its expression for 48h is not sufficient to significantly delocalize the protein to the 
cytoplasm or induce the formation of aggregates (Figure 4.8). For this reason, we 
focused on the truncated form of TDP43 lacking its C-terminal part by in vitro 
studies. The glycine-rich C-terminal domain resulted in playing a role in TDP43 
interaction with CSTF1 and its deletion impaired TDP43 activity in the regulation of 
alternative polyadenylation (Figure 4.9).  
Given the presented data, we propose a novel mechanism through which TDP43 
acts on alternative polyadenylation. When TDP43 binds its mRNA target in the 
3’UTR after the proximal polyA site, it prompts up there the recruitment of the CSTF 
complex, promoting the usage of the proximal PAS. The loss of the C-terminal 
domain in the pathological condition could be at the root of the alterations of 
alternative polyadenylation. To obtain a confirmation of the requirement of TDP43 
interaction with the CSTF complex, we will combine the TDP43 tethering between 
the proximal and distal PAS with the silencing of its three components, alone or in 
combination. In this way, we will also be able to include or exclude the role of CSTF2 
in the action of TDP43. Under the same silencing condition, we will also evaluate the 
effect on the alternative polyadenylation of TDP43 targets. 
Genes involved in cellular differentiation, synapse organization and nervous system 
development resulted significantly enriched in our list of differentially polyadenylated 
genes targeted by TDP43, leading us to hypothesize a role of TDP43 in neuronal 
cells mediated through the modulation of the alternative polyadenylation of some of 
its targets. To understand how APA changes could impact on TDP43 targets in the 
neuronal environment, we will clone the 3’UTR (long and short) of some targets, 
engineering specific reporters without the presence of any additional polyA site. The 
long form will be mutagenized at the level of the proximal PAS and/or the TDP43 
binding site. Then we will transfect them in primary culture of motor neurons, and we 
will analyze the expression, the translation efficiency, the cellular localization and the 
stability of the different isoforms. Moreover, we will test in Drosophila motor neurons 
if the silencing of the components of the CSTF complex could recapitulate the same 
phenotype observed in the absence of Tbph. In this way, we could suggest a direct 
link between alteration of alternative polyadenylation and neurodegeneration in vivo.
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6. EXPERIMENTAL PROCEDURES 
 
6.1 CELL CULTURE AND TREATMENTS 
 
Murine motor neuron-like hybrid NSC-34 cells and human HeLa cells were cultured 
in DMEM (Gibco) supplemented with 10% FBS (Gibco), 100 U/ml penicillin 
streptomycin (Gibco) and 0.01 mM l-glutamine (Gibco) and were incubated at 37 °C, 
5% CO2. 
For SILAC experiments, the cells were stable-isotope labeled under standard 
conditions as described in Paul et al., 2011. Heavy SILAC medium was prepared 
with DMEM lacking arginine and lysine (Gibco),10% dialyzed FBS (Gibco), 100 U/ml 
penicillin streptomycin (Gibco), 0.01 mM l-glutamine (Gibco),28 mg/l 13C615N4 L-
arginine and 49 mg/l13C615N2 L-lysine (Eurisotope). In ‘Light’ (L) SILAC medium were 
substituted with the corresponding non-labelled amino acids (Sigma). 
NMD was inhibited by 10 mM caffeine or 50 μg/mLcycloheximide (Sigma, C1988) 
treatment for 18 h. 
 
6.2 PLASMIDS CONSTRUCTS 
 
The genes (or part of them) were amplified from SK-N- BE(2) cDNA or plasmid with  
AccuPrime™ DNA polymerase (Invitrogen), using the primers indicated in Table 6.1. 
 
Table 6.1 Primers for cloning 
Gene 
Restriction   
site 
Primer sequence (5’-3’) Template 
hTDP43 Fw SgfI GAGGCGATCGCCTCTGAATATATTCGGGTAACC 
Cdna 
hTDP43 Rv MluI GCGACGCGTCTACATTCCCCAGCCAGAAGACTT 
hFus Fw SgfI GAGGCGATCGCCGCCTCAAACGATTATACCCAAC 
Cdna 
hFus Rv MluI GCGACGCGTTTAATACGGCCTCTCCCTGCGATC 
hTAF15 Fw SgfI GAGGCGATCGCCTCGGATTCTGGAAGTTACGGTCA pDEST_TO_TAF1
5 (Addgene 26378) hTAF15 Rv MluI GCGACGCGTTCAGTATGGTCGGTTGCGCTGAT 
hEWSR1 Fw SgfI GAGGCGATCGCCGCGTCCACGGATTACAGTACCTA pDEST_TO_EWS
R1 (Addgene 26376) hEWSR1 Rv MluI GCGACGCGTCTAGTAGGGCCGATCTCTGCGCTC 
hTDP43 
ΔCterm Rv 
MluI TTTTACGCGTATTGTGCTTAGGTTCGGC 
pCMV6-AN- His-
HA TDP43 wt 
hTDP43 Fw XhoI CGAGCTCGAGTCTGAATATATTCGGGTAACCGAA 
pCMV6-AN- His-
HA TDP43 wt 
hTDP43 Rv NotI GCGGCGGCCGCCTACATTCCCCAGCCAGAAGACTT 
pCMV6-AN- His-
HA TDP43 wt 
Note: h = human 
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The amplified fragments were cloned using SgfI and MluI sites into the pCMV6-AN- 
His-HA plasmid (OriGene, PS100017). The generated vectors express the gene of 
interest in fusion with an amino-terminal polyhistidine (His) tag and an hemagglutinin 
(HA) epitope. 
The vector pCI-MS2V5-TDP43 was generated using XhoI and NotI sites. 
pCI-MS2V5 expressing GST, Y14 and CSTF1, pCI-mVenus empty vector, and the 
reporter genes used in the tethering experiments are a generous gift of Niels 
Gehring. The vectors pCI-mVenus-TDP43 wt, -TDP43 ΔCterm, and –CSTF1 were 
produced using XhoI and NotI sites. 
The mutants were obtained via PCR-directed mutagenesis of the wild type template 
using the primers reported in Table 6.2. 
 
Table 6.2 Primers for mutagenesis 
Name primer (5’-3’) 
TDP43 W113A sense CTTTCAGGTCCTGTTCGGTTGTTTTCGCTGGGAGACCCAACAC 
TDP43 W113A antisense GTGTTGGGTCTCCCAGCGAAAACAACCGAACAGGACCTGAAAG 
TDP43 R151A sense TGTTTCATATTCCGTAAACGCAACAAAGCCAAACCCCTTTG 
TDP43 R151A antisense AAGGGGTTTGGCTTTGTTGCGTTTACGGAATATGAAACAC 
TDP43 Q331K sense CCAGGCAGCACTAAAGAGCAGTTGGGGTA 
TDP43 Q331K antisense TACCCCAACTGCTCTTTAGTGCTGCCTGG 
Globin_3UTR__XhoI asntisense TTTTTTCTCGAGTGCATGAATATCCTC 
Globin_delCrypt_polyA asntisense GCTTAGGGAACAAAGGAACCCTCAACAGAAATTGGACAGCAAGAAA 
Globin_EcoRI_exon3 sense TTTTTTGAATTCACCCCACCAGTG 
 
6.3 LENTIVIRUSES PRODUCTION 
 
The His-HA tagged genes were excised from pCMV6-HIS-HA plasmids and 
subcloned into the BamHI and XhoI sites of the vector pENTR1A (w48-1, Addgene). 
The resulting vectors were then recombined with pLenti CMV/TO Puro DEST (670-1, 
Addgene) using Gateway™ LR-Clonase (Life Technologies) to get the lentiviral 
vectors expressing tagged genes under the control of a doxycycline-inducible 
promoter. Lentiviruses were then prepared in accordance with the protocols detailed 
by Campeau et al., 2009. 
  
6.  EXPERIMENTAL PROCEDURES 
63 
 
6.4 TRANSDUCTION AND GENERATION OF TETRACYCLINE 
INDUCIBLE CELL LINES OVEREXPRESSING PROTEINS 
 
NSC-34 cells were transduced with the pLentiCMV_TetR_Blast vector (Addgene, 
716-1), constitutively expressing the tetracycline (Tet) repressor under the control of 
a CMV promoter, and selected for 10 days using 10 µg/ml Blasticidin (Sigma). The 
stable cells were infected with the lentiviral vectors in the presence of 4 µg/ml 
polybrene. The selection of transduced cells was then conducted by using 5 µg/ml 
puromycin. The protein overexpression was induced by adding 2 µg/ml doxycycline 
(Clontech) to the culture medium for 48 h and verified by Western blot analysis. 
HeLa Flp-In T-REx cells β-globin xrRNA WT and PTC are a generous gift of Niels 
Gehring. 
 
6.5 IMMUNOPRECIPITATION 
 
Forty-eight hours after induction or transfection, cells were harvested in lysis buffer 
(150 mM NaCl, 25 mM Tris-HCl, 10 mM MgCl2, 1% NP-40, 0.1% SDS,5% Glycerol) 
supplemented with complete protease inhibitor (Roche). Cell lysate was incubated 
with 30 μl (15 μl for Mass Spectrometry analysis) of anti-HA Magnetic Beads (Pierce) 
for 90’ at 4°C. The beads were then washed with wash buffer (150 mM NaCl, 25 mM 
Tris-HCl, 10 mM MgCl2, 0.025% NP-40). Bound proteins were eluted by boiling in 
SDS loading buffer and analyzed by Western blotting or with 8M guanidium 
hydrochloride and analyzed by MS. For SILAC-based quantitative 
immunoprecipitation beads from one heavy and one light experiment were mixed 
before elution and a label swap experiment was carried out (Figure 3.1a). 
 
6.6 PROTEIN PRECIPITATION AND IN-SOLUTION DIGESTION 
 
Eluted proteins from the immunoprecipitation were ethanol-precipitated and in 
solution-digested with lysyl endopeptidase (LysC) (Wako) and sequence-grade 
modified Trypsin (Promega). Stop and go extraction (STAGE) tips containing C18 
empore disks (3M) were used to purify and store peptide extracts (Rappsilber et al., 
2003). 
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6.7 LC-MS/MS AND DATA ANALYSIS 
 
Peptide mixture (2 uL) was separated by reversed phase chromatography using the 
EASY-nLC2 system (Thermo Scientific) on 20 cm silica fritless microcolumn (75 µm 
inner diameter packed in-house with ReproSil-Pur C18-AQ 3-µm resin, Dr.Maisch 
GmbH). Peptides were separated on a 5-75% acetonitrile gradient with 0.5% formic 
acid (30 min) at a nano flow rate of 200 nl/min. Eluted peptides were ionized by 
electrospray ionization and sprayed into a Q Exactive Plus mass spectrometer 
(Thermo Scientific). The MS and MS/MS spectra were processed with the MaxQuant 
platform version 1.5.2.8 (Cox and Mann, 2008). 
For SILAC experiments SILAC pairs were assembled from detected isotope 
patterns, recalibrated and quantified in the Quant module (heavy labels: Arg10 and 
Lys-8; maximum of 3 labelled aminoacids per peptide; maximum peptide charge of 
6; top 6 MS/MS peaks per 100 Da; polymer detection enabled). A maximum of 2 
missed cleavages were tolerated in the in silico digestion of the protein sequences. 
For protein identification, a minimum peptide length of 7 amino acids was required. 
Maximum false discovery rate was set at 1% for both peptide and protein 
identifications, estimated based on the reverse hits matched in the target-decoy 
database. Carbamidomethylation of cysteine was used as fixed modification. 
Oxidation of methionine and acetylation of the protein N-terminus were set as 
variable modifications. MS/MS spectra were searched by the internal Andromeda 
search engine against the Mus musculus protein database (ID UP000000589) and 
the database of common contaminants. 
 
6.8 WESTERN BLOT 
 
Protein samples derived from cells lysated with RIPA buffer, from 
immunoprecipitation or from TriFast extractions were resolved on SDS-PAGE and 
transferred to nitrocellulose membrane. Immunoblot analysis was performed with the 
following antibodies: anti-ACTININ (Santa Cruz Biotechnology, H-300), anti-
BARENTSZ (Sigma, HPA024592,a generous gift from Macchi’s lab), anti-CSTF1 
(Bethyl, A301-250A), anti-CSTF3 (Bethyl, A301-096A), anti-EIF4A3 (homemade 
antibody, a generous gift from Macchi’s lab), anti-GAPDH (Santa Cruz 
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Biotechnology, 6C5), anti-H3 (Abcam, ab1791), anti-HA (Bethyl, A190-108A), anti-
PABPC1 (Sigma, SAB2101708), anti-SMG1 (Santa Cruz Biotechnology, E-4), anti-
TDP43 (Proteintech, 10782-2-AP), anti-TUBULIN (Sigma, T6199), anti-UPF1 
(Bethyl, A301-902A), anti-V5 (QED Bioscience, 18870), anti-Y14 (Bethyl, A301-
033A), anti-mouse IgG-HRP (Santa CruzBiotechnology, sc-2005), anti-rabbit IgG-
HRP (Santa Cruz Biotechnology, sc-2004). ECL Prime and Select Western blotting 
detection reagents (GE Healthcare) in combination with Chemidoc (Biorad) were 
used for visualization. 
 
6.9 IMMUNOFLUORESCENCE MICROSCOPY 
 
After fixation in 4% PFA, cells were permeabilized in PBS + 0.1% Triton X-100 for 5 
min and incubated in blocking solution (2% bovine serum albumin, 2% fetal bovine 
serum, 0.2% gelatin in PBS) for 1 hour at RT. Primary antibodies were incubated 
overnight at RT in blocking solution diluted 1:10 in PBS. The following primary 
antibodies were used: rabbit anti-PABPC1 1:500 (Ab21060, Abcam), mouse anti-HA 
1:500 (Sigma). The following secondary antibodies, diluted 1:800, were used: goat 
anti-rabbit Alexa Fluor® 594 (A11012, Thermo Fisher Scientific), goat anti-mouse 
Alexa Fluor® 488 (A11017, Thermo Fisher Scientific). Nuclei were stained with 
DAPI. Images were acquired with Zeiss Observer Z.1 Microscope implemented with 
the Zeiss ApoTome device. Pictures were acquired using AxioVision imaging 
software package (Zeiss). Images were not modified other than adjustments of levels 
and brightness. 
 
6.10 TETHERING ASSAY 
 
2.7x105 HeLa cells were seeded in 6-well plates 24 h before transient transfection by 
calcium phosphate precipitation with 2 μg reporter plasmid, 1 μg of MS2V5-tagged 
expression plasmid, 0.5 μg transfection control plasmid (β-globin 300 + E3) and 0.5 
μg of pCI-mVenus plasmid. 
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6.11 siRNA TRANSFECTION 
 
HeLa cells (2,5x105 cells/well) or NSC-34 cells (4x105cells/well) were reverse 
transfected in 6-well plates using 2.5 ml Lipofectamine RNAiMAX (Thermo Fisher) 
and 60 pmol siRNA (Table 6.3), following the manufacturer’s protocol. 
 
Table 6.3 siRNA target sequences 
Target gene siRNA (5’-3’) Reference 
Luciferase CGUACGCGGAAUACUUCGAdTdT Miyagishi and Taira., 2002 
hSMG1 GUGUAUGUGCGCCAAAGUAdTdT Usuki et al., 2006 
hTDP43 GCAAAGCCAAGAUGAGCCUdTdT De Conti et al., 2015 
mUPF1 CAGUUACUGUGGAAUCCAUdTdT Mino et al., 2015 
mTDP43 CGAUGAACCCAUUGAAAUAdTdT Colombrita et al., 2012 
 
6.12 RNA EXTRACTION 
 
Total RNA was isolated using EUROGOLD TriFast (Euroclone) according to the 
manufacturer’s instructions. For cytoplasm-nucleus fractionation, the cells were 
harvested in polysome buffer (10 mMNaCl, 10 mM MgCl2, 10 mMTris-HCl pH 7.4, 
1% Triton X-100, 1% Na-deoxycholate and 1 mM DTT) and the fractions were 
separated by centrifugation before RNA purification. The RNA extraction from mouse 
spinal cord was performed after tissue homogenization with FastPrep®-24 system. 
 
6.13 NORTHERN BLOT 
 
RNA was resolved on a 1% agarose and 0.4 M formaldehyde gel using the tricine-
triethanolamine buffer system (Mansour et al., 2013) and analysed by Northern 
blotting.[α-32P]-GTP body-labelled RNA probes were used for reporter and control 
RNAs detection and in vitro transcribed using BamHI-linearized PSP65-globin 
plasmid as a template.7SL endogenous RNA was detected using a 5’-32P-labelled 
oligonucleotide (5’-TGCTCCGTTTCCGACCTGGGCCGGTTCACCCCTCCTT-3’). 
Signals were scanned with Typhoon FLA 7000 (GE Healthcare) and raw unmodified 
scans were quantified with ImageQuant TL (GE Healthcare). 
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6.14 RNA IMMUNOPRECIPITATION (RIP) 
 
Cells were harvested in polysome lysis buffer (100 mM KCl, 5 mM MgCl2, 10 mM 
HEPES pH 7.4, 0.5%NP-40) supplemented with 100 U RNase Out (Invitrogen) and 
complete protease inhibitor (Roche). 30  μl of anti-HA Magnetic Beads (Pierce) were 
added to500 μg of cell lysate in NT2 buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 
1 mM MgCl2,0.05%NP-40 supplemented with fresh 200 U RNase Out (Invitrogen), 
20 mM EDTA). 5% of the reaction mix was saved as input. After 3h of incubation at 
4°C, the immunoprecipitated complexes were washed 4 times with cold NT2 buffer 
supplemented with 0.5% Urea, 4 times with cold NT2 bufferand resuspended in 100 
μl NT2. RNA from immunoprecipitate and input was isolated with EUROGOLD 
TriFast (Euroclone) and analyzed by quantitative PCR. 
 
6.15 QUANTITATIVE PCR 
 
500 ng of total RNA were retrotranscribed with the iScript cDNA synthesis kit 
(Biorad). The obtained cDNA was used as template in qPCR reaction performed with 
KAPA SYBR FAST qPCR (Kapa Biosystem) and specific primers (Table 6.4). PCR 
conditions were 3 min at 95°C for initial denaturing, followed by 39 cycles of 10 sec 
at 95°C,20 sec at 60°C and 10 sec at 72°C. Ppia and Rpl10A were used as 
reference genes. The relative expression was calculated with the delta delta Ct 
method. 
Table 6.4 Primers for quantitative PCR 
target name forward primer (5’-3’) reverse primer (5’-3’) 
mAtg12 GAAATGGGCTGTGGAGCGAA TGCAGTAATGCAGGACCAGTT 
mGabarapl2 CATGGTGGCTCACAACCGTA TCTGTATGAATGCCCTATCTGC 
mPpia AACACAAACGGTTCCCAGTT CTTCCCAAAGACCACATGCT 
mRpl10a GAAGAAGGTGCTGTGTTTGGC TCGGTCATCTTCACGTGGC 
mScg2 TGCTTGGAGCCTTCCACATAA AAGCTGCTTCGGCTCCAGA 
mTdp43 AGAGCTTTTGCCTTCGTCACCT AAGAGACTGGGCAACCTTATCATC 
mUbe2v2 (long) CTTGTGTGAAGATCAGAGGT CCTTGTTGACACGCATGGTA 
mUbe2v2 (total) GTGTCTTAAGAGACTGTGCTA GCTGGCCAGGAACTTGTAAT 
mUpf1 AGATCACGGCACAGCAGAT CTCCAGAGTGGCTGAAGGAT 
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6.16 LIBRARY PREPARATION AND NEXT GENERATION 
SEQUENCING DATA ANALYSIS 
 
QuantSeq 3' mRNA-Seq Library Prep Kit REV (Lexogen) was used starting from 500 
ng of total RNA. For protocol details see Figure 4.2a. Paired end sequencing was 
performed with the Illumina HiSeq 2500 platform (Mus musculus, GPL17021). Fastq 
files were checked for quality control with FastQC. Adapter removal and flexible 
quality trimming was performed with Trimmomatic version 0.36. Processed reads 
generated from each sample were aligned to the mouse transcriptome with Bowtie2 
(version 2.2.6), using the Gencode M6 transcript annotation. All programs were used 
with default settings unless otherwise specified. Read pairs with 3'end mapping 
within 10bp from transcript end, corresponding to the polyadenylation cleavage site, 
were considered for quantification and estimation of transcript expression levels 
(using bedtools utilities version 2.17.0). Normalization among samples was 
performed with the edgeR Bioconductor package, using the TMM method (trimmed 
mean of M values). Only transcripts with signal exceeding 1 CPM (count per million) 
in at least one condition were kept for further analysis. 
 
6.16.1 FOR NMD (SIMPLE DIFFERENTIAL EXPRESSION ANALYSIS) 
 
Differential expression analysis was performed with edgeR using the glmQLFit 
method (Genewise Negative Binomial Generalized Linear Models With Quasi-
Likelihood Tests), selecting transcripts with statistical significance < 0.05. 
 
6.16.2 FOR APA (DIFFERENTIAL POLYADENYLATION ANALYSIS) 
 
Differential polyadenylation analysis was performed with edgeR using the 
diffSpliceDGE method, selecting transcripts with statistical significance < 0.1. P-
values were not corrected for multiple testing. Within each gene, only isoforms with 
transcript 3’ ends more distant than 10bp (in genomic coordinates) were considered 
as distinct polyadenylation sites. Polyadenylation usage values were defined as the 
percentage of signal associated with each isoform with respect to the total signal of 
the gene. 
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6.17 ANIMALS AND MOTOR TESTS 
 
Mice carrying a mutated TDP43 gene (B6N.Cg-Tg(Prnp-TARDBP*Q331K)103Dwc/J) 
and non-transgenic  littermate C57B6JN were purchased from Jackson Laboratories 
(Bar Harbor, ME, USA). The breeding and maintenance of the mouse colony were 
conducted in consultation with the veterinary staff. Animal care and experimental 
procedures were conducted in accordance with the University of Trento ethics 
committee and were approved by the Italian Ministry of Health. 
Cohorts of male transgenic and non-transgenic mice were followed weekly for 
general health and motor phenotype. For the hindlimb-clasping test, the mice were 
gently lifted by their tail for up to 10 s and extension of the limbs was tested for 
abnormal reﬂex. To evaluate motor coordination and balance, mice were tested for 
time to fall on accelerating rotarod test (Ugo Basile Instruments) starting from 3 
weeks of age until 10 months of age. Following a 1 week training session, trials were 
repeated weekly. Each session consisted of three tests of 300 s with an acceleration 
period (2–40 rpm) and a 5 min interval between trials. The time spent on the 
spinning wheel before falling was averaged over three trials. Statistical analysis was 
performed using one-way ANOVA test.  
For the tissue collection, mice were sacrificed at 3 months and 10 months of age 
using carbon dioxide euthanasia. The spinal cords were rapidly isolated with the 
ejection method (Meikle et al., 1981), flash frozen in liquid nitrogen and stored at -
80°C for RNA and protein extraction. 
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7. ADDENDUM 
 
Within the “AXonomIX project” (http://www.axonomix.eu/), whose aim is to identify 
the translational networks altered in motor neuron diseases, a large collection of cell 
models (Table 7.1) for Motor Neuron Diseases (MNDs) were produced. Amyotrophic 
Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) and Distal Spinal Muscular 
Atrophy type1 (DSMA type1) are a group of untreatable and lethal disorders 
characterized by progressive degeneration of upper and lower motor neurons in the 
central nervous system and weakness of muscles. 
Several RNA binding proteins involved in MNDs were cloned and mutagenized into 
double tagged-lentiviral vectors. These proteins are directly or indirectly associated 
with RNA processing (splicing, stability, transport and translation) and they are 
affected by MNDs-linked mutations. Mutations in TDP43, FUS, Angiogenin, TAF15, 
EWSR1, Ataxin-2 are associated with amyotrophic lateral sclerosis (ALS), disruption 
of SMN causes spinal muscular atrophy (SMA), and genetic alterations in IGHMBP2 
lead to distal spinal muscular atrophy type 1 (DSMA1). 
NSC-34 cell line was engeneered for the inducible expression of tagged wild type or 
mutant protein of interst. 
In addition to the cell models for MNDs-linked proteins overexpression, an in vitro 
model for Spinal Muscular Atrophy was generated by using CRISPR-Cas9 
technology (Figure 7.1a). SMA is caused by loss or mutation of 
the survival motor neuron1 gene (SMN1), which leads to insufficient expression of 
the functional full-length SMN protein (lower than 20%) and motor neuron 
dysfunction (Burghes and Beattie, 2009). The Survival Motor Neuron (SMN) gene 
was knocked-out in NSC-34 cells (Figure 7.1b); after clonal expansion, several cell 
lines with a defined SMN protein expression level were derived (Figure 7.1c). 
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Figure 7.1 SMA cell model. The RNA-guided Cas9 nuclease from the microbial clustered regularly 
interspaced short palindromic repeats (CRISPR) adaptive immune system was used to knockout the 
Survival Motor Neuron (SMN) in NSC-34 cell line. Cas9, guided by a RNA of 20 nucleotides, 
recognizes and binds a specific locus in the genome and produces a double strand break, which is 
repaired by non-homologous end joining (NHEJ). An indel mutation can be introduced, generating a 
premature stop codon. (a) NSC-34 cells, transfected with pX330 vector expressing Cas9 and 3 
different in silico designed guide RNAs (1A, 1B and 3), were selected with puromycin for 48 hrs. 
Starting from the pool of cells transfected with the guide 3, we performed a clonal expansion to derive 
cell lines with a defined SMN expression level. The SMN protein level was tested in the pool 
populations (b) and in 10 clones (c) by Western blot analysis. TUBULIN was used as protein loading 
control. 
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Table 7.1 Panel of produced plasmids and MND cell models 
 
Using some of these cell lines, we performed a label-free quantitative mass 
spectrometry analysis (Figure 7.2a) of the protein interactors of several MNDs-linked 
RBPs: FUS (Figure 7.2b), MATR3 (Figure 7.2c), EWSR1 (Figure 7.2d), TAF15 
(Figure 7.2e), ATXN2 (Figure 7.2f), and IGHMBP2 (Figure 7.2g). 
This high-throughput analysis provided a low number of significant specific 
interactors (Table 7.2), compared to the SILAC-based analysis performed on the 
TDP43 interactome (Table 3.1). However, our results evidenced, for some of the 
analyzed proteins, enrichment in components of NMD and mRNA 3’end processing 
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(Figure 7.2h, i and l), suggesting their possible involvement in these pathways, even 
if more validations are needed.  
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Figure 7.2 Protein interactome analysis of RBPs involved in MNDs. (a) Workflow of protein-
protein interaction analysis by label-free quantitative Mass Spectrometry. His-HA RBPs and His-HA 
GFP were overexpressed for 48 h in NSC-34 cell line. After the pull-down, captured bait/prey 
complexes were eluted and analyzed by LC-MS/MS. We performed the analysis in three independent 
experiments, without any treatment. For each quantified protein, the LFQ intensity (y axis) and the fold 
change between RBP pull-down and GFP pull-down (used as negative control, x-axis) are 
represented in the scatter plot. The number of identified high-confidence interacting proteins 
(highlighted in bigger dots) are indicated (fold-change > 1.5 and the t-test p value < 0.1). The 
enrichment analysis is presented in the bottom panel. We performed the interactome proteomic 
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analysis of (b) FUS, (c) MATR3, (d) EWSR1, (e) TAF15, (f) ATXN2, and (g) IGHMBP2. (h and l) 
Comparison between the TDP43 interactome analyzed by SILAC based approach and the protein 
interactors of other RBPs involved in MNDs identified by LFQ proteomics. (i) List of the proteins of the 
mRNA surveillance pathway (KEGG mmu03015) interacting with MNDs-linked RBPs.  
 
Table 7.2 Protein interactors of RBPs involved in MNDs 
RBP Interactors 
FUS 
1810009A15Rik, AU019823, Bcar1, Cpsf1, Cpsf2, Csnk2b, Ddx17, Dynll1, Fip1l1, Mphosph10, 
Mrpl34, Nop2, Pabpn1, Pgk1, Ptbp1, Rpl10a, Rps27, Snrnp70, Ssb, Taf15, Tmcc3, Usp28, 
Wdr46 
MATR3 
Bcar1, Chgb, Cpsf2, Dynll1, Hnrnpll, Krt76, Prdx1, Prpf38a, Psma2, Rnps1, Skp1, Tmcc3, 
Tmod3, Usp28 
EWSR1 
Anxa1, Anxa2, Bcar1, Caap1, Cat, Cpsf1, Ddx18, Prdx1, Prmt1, Prpf38a, Rps18, Rps9, 
Snrnp70, Srsf10, Txn, Usp28, Wdr33, Zcchc17 
TAF15 
Bcar1, Cpsf1, Ddx17, Dnaja1, Dynll1, Hdgfrp2, Myh14, Prmt1, Serping1, Snrnp70, Tecr, 
Tmcc3, Ywhaz 
ATXN2 
Aen, Atad3, Bcas2, Cpsf1, Csnk2b, Cyc1, Ddx18, Ddx46, Ddx52, Dync1h1, Dynll1, Eif4b, 
Fam195b, Fbl, Flii, Hdgfrp2, Hsd17b12, Hsph1, Khsrp, Larp4, Lsm12, Mfap1, Mrps5, Mybbp1a, 
Pabpc1, Pabpn1, Parp1, Pcbp2, Ppp2r1a, Prpf40a, Rbm25, Rbmx2, Rpl10a, Rpl7, Rps2, 
Rps9, Rsbn1, Rsrc2, Skp1, Srek1, Top2a, Tra2a, Upf1, Wdr46 
IGHMBP2 
Actr2, Add3, Bcar1, Caprin1, Capza1, Cherp, Cpsf2, Cpsf3, Csnk2b, Ddx17, Dstn, Flii, Fxr1, 
G3bp1, G3bp2, Gm17669, Gnb2l1, Lima1, Llph, Lrrfip2, Mprip, Myl1, Pabpc1, Prpf31, Ptbp1, 
Rbm28, Rcn2, Rpl10a, Rpl12, Rpl13, Rpl13a, Rpl14, Rpl15, Rpl18, Rpl18a, Rpl19, Rpl27, 
Rpl28, Rpl3, Rpl34, Rpl35a, Rpl37a, Rpl4, Rpl5, Rpl6, Rpl7, Rplp1, Rplp2, Rps10, Rps12, 
Rps15a, Rps16, Rps19, Rps21, Rps27, Rps27l, Rps28, Rps3, Rps5, Rps8, Rps9, Serbp1, 
Skp1, Tmcc3, Tpm1, Tpm2, Tpm4, Upf1, Vgf, Vimp, Wdr1, Ywhaq 
 
The produced cell lines represent a valuable resource and are suitable for in vitro 
studies, protein and RNA interactome analysis. Some of them were used in different 
projects that led to the following articles, and other papers are in preparation: 
Exosome derived from murine adipose-derived stromal cells: neuroprotective effect on in 
vitro model of amyotrophic lateral sclerosis. Raffaella Mariotti, Roberta Bonafede, Ilaria 
Scambi, Daniele Peroni, Valentina Potrich, Federico Boschi, Donatella Benati, Bruno Bonetti, 
Experimental Cell Research, 2016 Jan 1;340(1):150-8. doi: 10.1016/j.yexcr.2015.12.009 
In vivo translatome profiling reveals early defects in ribosome biology underlying SMA 
pathogenesis. Paola Bernabò, Toma Tebaldi, Ewout JN Groen, Fiona M Lane, Elena 
Perenthaler, Francesca Mattedi, Helen J Newbery, Haiyan Zhou, Paola Zuccotti, Valentina 
Potrich, Francesco Muntoni, Alessandro Quattrone, Thomas H Gillingwater, Gabriella Viero. 
Submitted doi: https://doi.org/10.1101/103481 
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